

Date Submitted: 2024-09-30 14:41:30

Confirmation Number: 1835387

Template: Full CV

Dr. FEI GENG

Correspondence language: English

Sex: Male

Date of Birth: 10/27

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

W Booth School of Engineering Practice

ETB-203

McMaster University

1200 Main Street West

CANADA (L8N 3Z5)

Hamilton Ontario L8N 3Z5

Canada

Telephone

Mobile (*) 001-905-9029163

Work 001-905-5259140 extension: 20285

Email

Work (*) gengf@mcmaster.ca

Website

Personal <https://www.eng.mcmaster.ca/people/faculty/fei-geng>

Dr. FEI GENG**Language Skills**

| Language | Read | Write | Speak | Understand | Peer Review |
|----------|------|-------|-------|------------|-------------|
| English | Yes | Yes | Yes | Yes | Yes |
| French | No | No | No | No | No |

Degrees

| | |
|------------------|--|
| 2004/9 - 2011/12 | Doctorate, Doctor of Philosophy, Biochemistry and Biomedical Sciences, McMaster University Degree Status: Completed Thesis Title: Cell Death Mechanisms at the Endoplasmic Reticulum |
| 2001/9 - 2004/8 | Master's Thesis, Master of Science, Biochemistry and Molecular Biology, Fudan University Degree Status: Completed |
| 1996/9 - 2001/7 | Bachelor's Honours, Bachelor of Medicine, Clinical Medicine, Jining Medical College Degree Status: Completed |

Credentials

| | |
|--------|--|
| 2016/2 | P.Eng., Professional Engineers Ontario |
|--------|--|

Recognitions

| | |
|-----------------|---|
| 2021/8 | Michael G. DeGroote Institute Research Award McMaster University Prize / Award This award is to recognize the research excellence in the area of Pain Research. |
| 2018/9 - 2019/4 | Dean's Honor Roll McMaster University Prize / Award This award is to recognize the top professors in teaching and research in Faculty of Engineering at McMaster University. |

User Profile

Engaged in Clinical Research?: No

Research Specialization Keywords: Cellular Mechanotransduction, Fluorescence Lifetime Imaging Microscopy, YAP/TAZ Signaling in Live-cell System

Disciplines Trained In: Biomedical Engineering and Biochemical Engineering

Research Disciplines: Biomedical Engineering and Biochemical Engineering, Biology and Related Sciences, Chemical Engineering

Areas of Research: Nanoparticles, Biotechnology

Fields of Application: Pathogenesis and Treatment of Diseases, Biomedical Aspects of Human Health

Employment

| | |
|--------|---|
| 2022/3 | Associate Professor W Booth School of Engineering Practice and Technology, Engineering, McMaster University Full-time, Associate Professor Tenure Status: Tenure Research Disciplines: Biomedical Engineering and Biochemical Engineering Areas of Research: Biotechnology Fields of Application: Biomedical Aspects of Human Health |
| 2020/7 | Program Chair in Biotechnology W Booth School of Engineering Practice and Technology, Engineering, McMaster University Full-time, Term Tenure Status: Tenure Track Research Disciplines: Biomedical Engineering and Biochemical Engineering Areas of Research: Biotechnology Fields of Application: Biomedical Aspects of Human Health |
| 2019/4 | Assistant Professor W Booth School of Engineering Practice and Technology, Engineering, McMaster University Full-time, Assistant Professor Tenure Status: Tenure Track My research team utilizes an interdisciplinary research approach that combines biomechanics, biophysics, cell and molecular biology, and focuses on the mechanotransduction studies. My research is funded by Scleroderma Society Of Ontario and Mitacs grants. Research Disciplines: Biomedical Engineering and Biochemical Engineering Areas of Research: Biotechnology Fields of Application: Biomedical Aspects of Human Health |

Affiliations

The primary affiliation is denoted by (*)

(*) 2013/5 Associate Professor, McMaster University

Research Funding History

Awarded [n=6]

2024/7 - 2025/7 Advancing Early Detection of Lung Cancer through Multiplex Lateral Flow-Based Liquid
Principal Investigator Biopsy: A Blood Based Pre-Screening Approach, Grant

Funding Sources:

AstraZeneca Canada Inc.
 Lung Ambition Award
 Total Funding - 50,000
 Portion of Funding Received - 50,000
 Funding Competitive?: Yes

2022/9 - 2024/8

Principal Investigator

YAP mechanotransduction in autophagy and tumor metastasis, Grant

Funding Sources:

Mathematics of Information Technology and Complex Systems (MITACS)
 Accelerate
 Total Funding - 60,000
 Portion of Funding Received - 60,000
 Funding Competitive?: Yes

2019/10 - 2022/12

Principal Applicant

Targeting platelet-neutrophil axis: a novel therapeutic approach for Scleroderma, Grant

Funding Sources:

Mathematics of Information Technology and Complex Systems (MITACS)
 Accelerate
 Total Funding - 60,000
 Portion of Funding Received - 45,000
 Funding Competitive?: Yes

2021/8 - 2022/7

Principal Applicant

The proteomic profiling of pain signatures for post-surgical patients, Grant

Funding Sources:

Michael G. DeGroote Institute for Pain Research and Care
 IPRC Catalyst Grant
 Total Funding - 60,000
 Portion of Funding Received - 30,000
 Funding Competitive?: Yes

2018/2 - 2022/2

Co-applicant

Development of cost-effective label-free protein biosensors using magnetic bio-inks, Grant

Funding Sources:

Natural Sciences and Engineering Research Council of Canada (NSERC)
 Collaborative Research and Development (CRD) Grant
 Total Funding - 565,000
 Portion of Funding Received - 565,000
 Funding Competitive?: Yes

Principal Applicant : Ishwar Puri

2018/11 - 2020/11

Principal Applicant

The molecular mechanism of autophagy in systemic sclerosis and its clinical implication, Grant

Funding Sources:

2018/11 - 2020/11 Scleroderma Society of Ontario
 Scleroderma Research Grant
 Total Funding - 25,000 (Canadian dollar)
 Portion of Funding Received - 25,000
 Funding Competitive?: Yes

Student/Postdoctoral Supervision

Master's Thesis [n=3]

| | |
|----------------------|---|
| 2022/1 - 2024/1 | Zhi Su, McMaster University |
| Principal Supervisor | Thesis/Project Title: YAP regulation in the mechanotransduction of breast cancer metastasis Present Position: Master's student |
| 2022/1 - 2023/12 | Yuning Wu, McMaster University |
| Principal Supervisor | Thesis/Project Title: Beta-catenin regulation in the mechanotransduction of breast cancer metastasis Present Position: Master's student |
| 2019/9 - 2022/8 | Wei Chen (In Progress) , McMaster University |
| Principal Supervisor | Thesis/Project Title: The regulation of YAP signaling network in cellular mechanotransduction Present Position: Scientist, McMaster University |

Doctorate [n=3]

| | |
|----------------------|--|
| 2020/9 - 2025/8 | Arjun Raha (In Progress) , McMaster University |
| Principal Supervisor | Thesis/Project Title: The significance of O-GlcNAcylation in YAP mediated mechanotransduction Present Position: Ph.D. student, McMaster University |
| 2018/11 - 2022/8 | Tamaghna Gupta (In Progress) , McMaster University |
| Co-Supervisor | Student Degree Start Date: 2018/11 Student Degree Expected Date: 2022/8 Thesis/Project Title: The development of 3D cell culture system for cellular mechanotransduction studies Project Description: The development of 3D cell culture system for cellular mechanotransduction studies. The project focuses on the development of a novel cell compression system and the utilization of this system to investigate the mechanisms underlying the response of cells to mechanical forces. We aim to design, fabricate, calibrate, and apply an integrated compression system enabling high-throughput mechanotransduction studies. Then this system will be introduced to a more complex environment with micropost array in order to mimic the in vivo micromechanical environment. Using this advanced research model we will investigate the mechanisms by which mechanical forces and the mechanics of the cellular microenvironment are sensed and converted into biochemical signals. Present Position: Ph.D. student, McMaster University |

2018/1 - 2021/1
Co-Supervisor Sarah Mishriki (In Progress) , McMaster University
Student Degree Start Date: 2018/1
Student Degree Expected Date: 2021/1
Thesis/Project Title: In situ 3D cell assemblies through a contactless method-
diamagnetophoresis
Project Description: A magnet array is employed to manipulate diamagnetic cells that are contained in paramagnetic medium to demonstrate for the first time the contactless bioprinting of three-dimensional (3D) cellular structures and co-cultures of breast cancer MCF-7 and endothelial HUVEC at prescribed locations on tissue culture treated well plates. Sequential seeding of different cell lines and the spatial displacement of the magnet array creates co-cultured cellular structures within a well without using physically intrusive well inserts. Both monotypic and co-culture experiments produce morphologically rich 3D cell structures that are otherwise absent in regular monolayer cell cultures.
Present Position: Ph.D. candidate, McMaster University

Post-doctorate [n=2]

2022/7 - 2024/7
Principal Supervisor Yiting Tsai, McMaster University
Thesis/Project Title: Biomarker discovery and proteomic profiling via machine learning
Present Position: Postdoc Fellow

2020/5 - 2022/5
Principal Supervisor Saeed Mohammadi (In Progress) , McMaster University
Thesis/Project Title: The development of extracellular matrix with tunable stiffness for the mechanotransduction study
Present Position: Postdoctoral researcher, McMaster University

Event Administration

2020/10 - 2020/10 Conference chair, Interactive Collaborative and Blended Learning – ICBL2020, Conference, 2020/10 - 2020/10

Editorial Activities

2015/12 - 2025/12 Review Editor, Frontiers in Biomedical Physics, Journal

2019/7 - 2025/7 Reviewer, ACS Omega, Journal

2015/5 - 2025/5 Review Editor, Frontiers in Physiology, Journal

Committee Memberships

2020/5 - 2022/5 Committee Member, Departmental Research Excellence Committee, McMaster University

Other Memberships

2019/6 - 2026/6 Member, IEEE Engineering in Medicine & Biology Society

2019/9 - 2025/9 Member, American Society for Cell Biology

2019/7 - 2025/7 Member, Canadian Cancer Research Alliance

Presentations

1. Fei Geng. (2021). The regulation of breast cancer metastasis by YAP mechanotransduction. 64th Annual Conference of the Canadian Society of Molecular Biosciences (CSMB), Canada
Main Audience: Researcher
Invited?: No, Keynote?: No
2. Fei Geng. (2019). The regulation of autophagy via YAP signaling in systemic sclerosis. The 25th Canadian Connective Tissue Conference, Montreal, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No
3. Sarah Mishriki, Fei Geng. (2018). Magnetic Printing of a Biosensor: Inexpensive Rapid Sensing To Detect Picomolar Amounts of Antigen with Antibody- Functionalized Carbon Nanotubes. 28th Anniversary World Congress on Biosensors, Miami, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No
4. Sarah Mishriki, Fei Geng. (2018). Magnetic Antibody Functionalized Carbon Nanotube Ink for Rapid Printing of Biosensors. International Mechanical Engineering Congress & Exposition (IMECE), Pittsburgh, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No
5. Sarah Mishriki, Fei Geng. (2018). In Situ Contactless 3D Printing of Cellular Structures. International Mechanical Engineering Congress & Exposition, Pittsburgh, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Publications

Journal Articles

1. Su Z, Wu Y, Ge C, Barooj S, Hirota JA, Geng F. (2024). Deciphering the Mechanotransduction Symphony: Stiffness-Dependent Interplay of YAP and β -Catenin in Breast Cancer Metastasis. iScience. In Press,
Refereed?: Yes
2. Grewal, R*; Ortega, GA; Geng, F; Srinivasan, S; Rajabzadeh, AR. (2024). Label-free electrochemical detection of glycated hemoglobin (HbA1c) and C-reactive protein (CRP) to predict the maturation of coronary heart disease due to diabetes. Bioelectrochemistry. 159: 108743.
Published,
Refereed?: Yes, Open Access?: Yes
3. Ge, C*; Selvaganapathy, PR; Geng, F. (2023). Advancing our understanding of bioreactors for industrial-sized cell culture: health care and cellular agriculture implications. American Journal of Physiology-Cell Physiology. 20230724: 20230724.
Published,
Refereed?: Yes
4. Raha, A; Wu, Y; Zhong, L; Raveenthiran, J; Hong, M; Taiyab, A; Wang, L; Wang, B; Geng F. (2023). Exploring Piezo1, Piezo2, and TMEM150C in Human Brain Tissues and Their Correlation with Brain Biomechanical Characteristics. Molecular Brain. 16: 83.
Published,
Refereed?: Yes, Open Access?: Yes

5. Tsai, Y; Nanthakumar, V; Mohammadi, S; Baldwin, SA; Gopaluni, B; Geng F. (2023). Targeted Deep Learning Classification and Feature Extraction for Clinical Diagnosis. *iScience*. 26(11): 108006.
Published,
Refereed?: Yes, Open Access?: Yes
6. Song, X; Lin, CY; Raha, A, Ke, Y, Wang, L, Geng, F; You, L. (2022). Vibration in Preventing Breast Cancer Bone Metastasis. *Journal of bone and mineral research*. 37: 202.
Published,
Refereed?: Yes
7. Wang, Y; et al. (2022). The CaT stretcher: An open-source system for delivering uniaxial strain to cells and tissues (CaT). *Frontiers in Bioengineering and Biotechnology*. 10: 959335.
Published,
Refereed?: Yes
8. Wasi, M; Wang, S; Xiong, J; Geng, F; You, L; Wang, L. (2022). Longitudinal Monitoring of Breast Cancer-Induced Osteolysis in Aged Female Mice. *Journal of bone and mineral research*. 37: 202-203.
Published,
Refereed?: Yes
- [9.](#) *Yu, W; *Bai, Y; *Raha, A, *Su, Z; Geng, F. (2022). Integrative In Silico Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2. *Front. Bioinform.* 11 January 2022: 11 January 2022.
Published,
Refereed?: Yes
10. Lin, CY; Song, X; Ke, Y; Raha, A; Wu, Y; Wasi, M; Wang, L; Geng, F; You, L. (2022). Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration. *Cancers*. 14(14): 3395.
Published,
Refereed?: Yes
11. Chen, W*; Park, S*; Patel, C*; Bai, Y*; Henary, K*; Raha, A*; Mohammadi, S; You, L; Geng, F. (2021). The migration of metastatic breast cancer cells is regulated by matrix stiffness via YAP signalling. *Heliyon*. 7(2): e06252.
Published,
Refereed?: Yes, Open Access?: Yes
12. Gupta, T*; Aithal, S; Mishriki, S*; Sahu, RP; Geng, F; Puri IK. (2020). Label-Free Magnetic-Field-Assisted Assembly of Layer-on-Layer Cellular Structures. *ACS Biomaterials Science & Engineering*. 6(7): 4294-4303.
Published,
Refereed?: Yes, Open Access?: No
- [13.](#) Mishriki, S; Aithal, S; Gupta, T; Sahu, RP; Geng, F; Puri IK. (2020). Fibroblasts Accelerate Formation and Improve Reproducibility of 3D Cellular Structures Printed with Magnetic Assistance. *Research*. 2020: 3970530.
Published,
Refereed?: Yes, Open Access?: Yes
- [14.](#) Kong,Q; Xiang,Z; Wu,Y; Gu,Y; Guo,J; Geng,F. (2020). Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.*Mol Cancer*. 19(1): 80.
Published,
Refereed?: Yes, Open Access?: Yes
15. Chen,W*; Bai,Y*; Patel,C*; Geng,F. (2019). Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization. *Biochem Biophys Res Commun*.520(2): 263-268.
Published,
Refereed?: Yes

16. Abdel Fattah,A*; Mishriki,S*; Kammann,T; Sahu,R*; Geng,F; Puri,I. (2018). Gadopentetic acid affects in vitro proliferation and doxorubicin response in human breast adenocarcinoma cells. *Biometals*. 31(4): 605-616.
Published,
Refereed?: Yes, Open Access?: No
17. Abdel Fattah,A*; Mishriki,S*; Kammann,T; Sahu,R*; Geng,F; Puri,I. (2018). 3D cellular structures and co-cultures formed through the contactless magnetic manipulation of cells on adherent surfaces. *Biomaterials Science*. 6(3): 683-694.
Published,
Refereed?: Yes, Open Access?: No
18. Mishriki,S*; Abdel Fattah,A*; Kammann,T; Sahu,R*; Geng,F; Puri,I. (2018). Rapid magnetic 3D printing of cellular structures with MCF-7 cell inks. *Research*. 2019: 9854593.
Published,
Refereed?: Yes, Open Access?: No

Conference Publications

1. Chen, W*; Raha, A*; Geng, F. (2021). The regulation of breast cancer metastasis by YAP mechanotransduction. 64th Annual Conference of the Canadian Society of Molecular Biosciences (CSMB), Montréal, Canada,
Conference Date: 2021/6
Abstract
Published
Refereed?: Yes, Invited?: No
2. Chen W*, Patel C*, Bai Y*, Geng F. (2019). The regulation of autophagy via YAP signaling in systemic sclerosis. The 25th Canadian Connective Tissue Conference, Montreal, Canada,
Conference Date: 2019/5
Abstract
Published
Refereed?: Yes, Invited?: Yes
3. Abdel Fattah AR*, Abdalla AM, Mishriki S*, Meleca E*, Ghosh S*, Geng F, Puri IK. (2018). Magnetic printing of a biosensor: inexpensive rapid sensing to detect picomolar amounts of antigen with antibody-functionalized carbon nanotubes. 28th Anniversary World Congress on Biosensors, Miami, United States of America,
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: Yes
4. Mishriki S*, Geng F. (2018). In situ contactless 3D printing of cellular structures. International Mechanical Engineering Congress & Exposition (IMECE) 2018, Pittsburgh, PA, United States of America,
Conference Date: 2018/11
Abstract
Last Author
Published
Refereed?: Yes, Invited?: Yes

5. Mishriki S*, Geng F. (2018). Magnetic antibody functionalized carbon nanotube ink for rapid printing of biosensors. International Mechanical Engineering Congress & Exposition (IMECE) 2018, Pittsburgh, PA, United States of America,
Conference Date: 2018/11
Abstract
Last Author
Published
Refereed?: Yes, Invited?: Yes

Intellectual Property

Licenses

1. P.Eng.
Granted
Date Issued: 2016/2
Filing Date: 2023/03/16
The Professional Engineer License facilitates my engineering research and teaching activities in Faculty of Engineering at McMaster University. It keeps me up to date in my profession as bioengineer and involves me in professional development.

Date Submitted: 2024-02-27 15:55:59

Confirmation Number: 1750479

Template: Full CV

Dr. Rosalyn Juergens

Correspondence language: English

Sex: Female

Date of Birth: 8/23

Canadian Residency Status: Permanent Resident

Permanent Residency Start Date: 2010/12/20

Country of Citizenship: United States of America

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

699 Concession Street
Juravinski Cancer Centre
Fourth Floor - Room 228
Hamilton Ontario L8V 5C2
Canada

Telephone

Work (*) 1-905-3879495 extension: 63123

Email

Work (*) juergensr@hhsc.ca

Website

Corporate <https://experts.mcmaster.ca/display/juergen>
Corporate <http://www.everypatientmatters.ca/researchers/9>

Dr. Rosalyn Juergens

Language Skills

| Language | Read | Write | Speak | Understand | Peer Review |
|----------|------|-------|-------|------------|-------------|
| English | Yes | Yes | Yes | Yes | |
| French | No | No | No | No | |

Degrees

| | |
|-----------------|---|
| 2004/8 - 2012/5 | Doctorate, PhD, Clinical Investigation, Johns Hopkins University Degree Status: Completed Thesis Title: Targeting Epigenetic Changes in Lung Cancer Supervisors: Charles Rudin, MD PhD Research Disciplines: Oncology Areas of Research: Lung Cancer Fields of Application: Pathogenesis and Treatment of Diseases |
| 2003/7 - 2006/6 | Doctorate, Medical Oncology Fellowship - Fellow, Medical Oncology, Johns Hopkins University Degree Status: Completed Supervisors: Ross Donehower, MD |
| 2000/7 - 2003/6 | Doctorate, Internal Medicine Internship and Residency, Internal Medicine, Johns Hopkins University Degree Status: Completed Supervisors: Charles Weiner, MD |
| 1996/8 - 2000/5 | Doctorate, M.D., Medicine, Georgetown University Degree Status: Completed Supervisors: Mitchell, Stephen |
| 1992/8 - 1996/5 | Bachelor's, Bachelor of Science, Biological Research, Loras College Degree Status: Completed Thesis Title: Identification of Proteins Binding to the Brachial Regulatory Element of the Brachial Spinal Chord Enhancer of Murine Homeobox Gene A5 Supervisors: Eagleson, Gerald Research Disciplines: Molecular Biology Areas of Research: Biological and Biochemical Mechanisms |

Credentials

| | |
|------------------|---|
| 2011/1 | License to practice medical oncology, College of Physicians and Surgeons of Ontario Medical Oncology |
| 2006/1 | Board Certification in Medical Oncology, American Board of Internal Medicine Medical Oncology |
| 2003/1 - 2023/5 | License to practice medicine, Maryland Board of Physicians Internal Medicine and Medical Oncology |
| 2003/1 - 2013/12 | Board Certification in Internal Medicine, American Board of Internal Medicine Internal Medicine |

Recognitions

| | |
|--------|---|
| | Teacher of the Year - Medical Oncology (Canadian dollar) McMaster University Distinction |
| 2021/6 | American Society of Clinical Oncology - Women Who Conquer Cancer Award Finalist (Canadian dollar) Distinction |
| 2018/6 | Teacher of the Year - Medical Oncology McMaster University Distinction |
| 2018/4 | Phase III Program Team Award Canadian Cancer Trials Group Prize / Award |
| 2016/4 | Investigational New Drug Program Team Award Canadian Cancer Trials Group Prize / Award |
| 2012/5 | Membership in Delta Omega Johns Hopkins University Distinction Membership in public health honor society |
| 2012/5 | Membership in Phi Beta Kappa Johns Hopkins University Distinction Membership in academic honor society |
| 2005/5 | Clinical Researcher Annual International Award Johns Hopkins Bloomberg School of Public Health Distinction Clinical Research |
| 1999/5 | Alpha Omega Alpha Georgetown University Distinction |

User Profile

Researcher Status: Researcher
 Research Career Start Date: 2007/07/01
 Engaged in Clinical Research?: Yes

Research Interests: I have interests in multiple areas of clinical and translational research. I have focused mainly on lung and esophageal cancers. My key interests include epigenetics, immune-based therapies, genetically and epigenetically directed therapy, biomarkers in cancer, and functional imaging using PET.

Research Experience Summary: I have been involved as a principal investigator in numerous clinical trials. I have clinical research experience with several immune based therapies (such as PD-1 inhibitors and tumour directed viruses) as well as epigenetic directed therapy (demethylating agents and histone deacetylase inhibitors). In addition to my clinical research work I have contributed to at least weekly meetings with my basic science collaborators in epigenetics helping to guide pre-clinical experiments and taking laboratory experiment data back to inform our clinical trial development.

Research Specialization Keywords: clinical research, developmental therapeutics, epigenetics, esophageal cancer, Immunotherapy, lung cancer, molecular imaging, translational research

Disciplines Trained In: Epidemiology and Biostatistics, Molecular Biology, Oncology

Research Disciplines: Molecular Biology, Nuclear Medicine, Oncology

Areas of Research: Cancer Diagnosis and Detection, Cancer Genetics, Cancer of the Digestive System, Chemotherapy, Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

Employment

| | |
|------------------|---|
| 2023/4 | Early Trials Advisory Group Member - Canadian Cancer Trials Group |
| 2016/9 | Chair, Clinical Trials, Juravinski Cancer Centre Oncology, McMaster University, Juravinski Cancer Centre Full-time, Term, Associate Professor |
| 2016/7 | Associate Professor Oncology, McMaster University, McMaster University Full-time, Associate Professor |
| 2015/7 | Chair, Medical Advisory Committee Lung Cancer Canada |
| 2011/1 | Assistant Professor Department of Oncology, McMaster University, McMaster University Full-time, Assistant Professor |
| 2011/1 | Adjunct Assistant Professor Department of Oncology, The Johns Hopkins University, Johns Hopkins University Part-time, Assistant Professor |
| 2017/5 - 2024/4 | Investigational New Drug Committee - Executive member Canadian Cancer Trials Group |
| 2013/3 - 2023/7 | Chair, Lung Disease Site Team Juravinski Cancer Centre |
| 2019/5 - 2021/11 | Chair, Investigational New Drug Committee Canadian Cancer Trials Group |
| 2009/7 - 2010/12 | Assistant Professor Medicine, The Johns Hopkins University, Johns Hopkins University Full-time, Assistant Professor |
| 2007/7 - 2010/12 | Assistant Professor Department of Oncology, The Johns Hopkins University, Johns Hopkins University Full-time, Assistant Professor |

2006/7 - 2007/6 Chief Fellow - Medical Oncology
Department of Oncology, The Johns Hopkins University, Johns Hopkins University
Full-time

Affiliations

The primary affiliation is denoted by (*)

(*) 2016/7 Associate Professor, McMaster University

2011/1 Assistant Professor, McMaster University

Leaves of Absence and Impact on Research

2012/11 - 2013/6 Parental, McMaster University
I was on pregnancy / parental leave from late November 2012 through the end of May 2013. During this period I had reduced activity in my translational research endeavours.

2011/4 - 2011/9 Parental, McMaster University
Maternity leave

Research Funding History

Awarded [n=24]

2022/4 - 2027/3 Canadian Cancer Clinical Trials Network Cancer Centre Grant, Grant, Operating
Principal Applicant

2024/4 - 2026/3 GUT-INSTINCTS- Understanding the effect of the microbiome on response to
Principal Investigator neoadjuvant treatment with chemotherapy + immunotherapy in patients with resectable
non-small cell lung cancer (NSCLC)., Grant, Operating
Clinical Research Project?: Yes

Funding Sources:

Hamilton Academic Health Sciences Organization
Total Funding - 177,294 (Canadian dollar) (Canadian dollar)

2024/1 - 2025/6 MATCH 3.0: Liquid vs solid tissue biopsy for mutation and translocation detection in non-
Co-investigator squamous non-small cell lung cancer., Grant, Operating
Clinical Research Project?: Yes

Funding Sources:

Hamilton Health Sciences Foundation
Total Funding - 100,000 (Canadian dollar) (Canadian dollar)

2024/1 - 2025/1 Liquid vs solid tissue biopsy for mutation and translocation detection in non-squamous
Principal Applicant non-small cell lung cancer: Improving equity in cancer care delivery across Central-West
Ontario., Grant, Operating
Clinical Research Project?: Yes

Funding Sources:

Pfizer Canada, Lung Health Foundation; Lung Cancer Canada;
Quebec Lung Association
Total Funding - 100,000 (Canadian dollar) (Canadian dollar)

2024/1 - 2024/1 MATCH 2.0: Liquid vs solid tissue biopsy for mutation and translocation detection in non-
Co-investigator squamous non-small cell lung cancer: Improving equity in cancer care delivery across
Central-West Ontario., Grant

Clinical Research Project?: Yes

Funding Sources:

AstraZeneca Canada Inc.
Total Funding - 150,000 (Canadian dollar) (Canadian dollar)

2018/4 - 2022/3
Principal Applicant Canadian Cancer Clinical Trials Network Cancer Centre Grant, Grant, Grant, Operating

2017/9 - 2021/8
Principal Investigator Drug Resistance in Bodily Fluids Evaluation (DRIBLE)

Funding Sources:

2017/9 - 2019/8 AstraZeneca Canada Inc.
-
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

2017/6 - 2021/1
Principal Investigator Optimization of PD-L1 Testing in Hamilton

Funding Sources:

2017/6 - 2019/1 Merck Sharp & Dohme - Canada
IIT
Total Funding - 40,000 (Canadian dollar)
Funding Competitive?: No

2017/9 - 2019/8
Principal Investigator Utility of PD-L1 Testing in 2nd line NSCLC - Substudy of CA209-169

Funding Sources:

2017/2 - 2018/8 Bristol-Myers Squibb Canada Inc.
-
Total Funding - 33,000 (Canadian dollar)
Funding Competitive?: Yes

2014/4 - 2019/3
Principal Applicant Pilot of platform molecular testing in lung cancer

Funding Sources:

2014/5 - 2016/4 Juravinski Cancer Centre Foundation
Annual Gala Competition
Total Funding - 75,000 (Canadian dollar)
Funding Competitive?: Yes

Co-investigator : Elizabeth McCready; JC Cutz; Peter Ellis

2017/9 - 2018/8
Co-knowledge User Developing a Tool to Support Earlier Palliative Care

Funding Sources:

2017/9 - 2018/8 Canadian Institutes of Health Research (CIHR)
-
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

Principal Investigator : Hsien Seow

2015/8 - 2017/7
Principal Applicant A phase IB study of durvalumab (MEDI4736) with or without tremelimumab in patients with advanced incurable solid malignancies receiving standard chemotherapy regimens, Contract
Clinical Research Project?: Yes

Funding Sources:

2015/8 - 2017/7 National Cancer Institute of Canada (NCIC)
 Total Funding - 125,000 (Canadian dollar)
 Funding Competitive?: No

2015/7 - 2017/6 A randomized phase II trial of maintenance therapy with talazoparib or placebo in patients
 Principal Applicant with extensive disease small cell lung cancer, Contract
 Clinical Research Project?: Yes

Funding Sources:

2015/7 - 2017/6 National Cancer Institute of Canada (NCIC)
 Total Funding - 69,000 (Canadian dollar)
 Funding Competitive?: No

2011/1 - 2017/6 Imaging scientist award for development of translational research coordinating medical
 Principal Investigator oncology therapeutics and investigational imaging technologies.

Funding Sources:

2011/1 - 2016/12 Ontario Institute for Cancer Research (OICR)
 Investigator Awards Program
 Total Funding - 1,450,000 (Canadian dollar)
 Funding Competitive?: Yes

Principal Investigator : Rosalyn Juergens

2014/12 - 2016/11 Leveraging Research Discoveries in Hamilton: A Collaborative Clinical Study on Targeted
 Principal Investigator Alpha Radionuclide Therapy for Treatment Resistant Cancers

Funding Sources:

2014/11 - 2016/10 Boris Family Award
 Boris Scholars Award
 Total Funding - 294,500 (Canadian dollar)
 Funding Competitive?: Yes

Co-investigator : John Valliant; Karen Gulenchyn; Mark Levine

2009/12 - 2016/11 Bringing epigenetic therapy to the forefront of cancer management
 Co-investigator

Funding Sources:

2009/12 - 2012/11 American Association of Cancer Research (AACR)
 Stand up to Cancer Dream Team - SU2C-AACR-CT0109
 Total Funding - 2,337,852 (United States dollar)
 Funding Competitive?: Yes

Principal Investigator : Baylin, Stephen

2014/5 - 2015/4 Phase Ia, multi-centre, open-label, non-randomized study to assess the safety,
 Principal Investigator biodistribution and tumour uptake of [I-124]-CPD-1028 Injection

Funding Sources:

2014/5 - 2015/4 Centre for Probe Development and Commercialization
 Phase I development program in novel imaging probes
 Total Funding - 150,000 (Canadian dollar)
 Funding Competitive?: No

Co-investigator : Bane, Anita; Gulenchyn, Karen; Hotte, Sebastien; McWhirter, Elaine;
 Mukherjee, Som; Singnurkar, Amit

2013/4 - 2015/3 Evaluation of a patient-focused, nurse navigated esophageal cancer disease management
 Co-applicant pathway program

Funding Sources:

2013/4 - 2015/3 Hamilton Academic Health Sciences Organization (HAHSO)
 Innovation Grant Program
 Total Funding - 177,260 (Canadian dollar)
 Funding Competitive?: Yes

Co-applicant : Boylan, Colm; Dhesy-Thind, Sukhbinder; Farrokhyar, Forough; Shargall, Yaron; Sur, Ranjan; Woods, Anne;

Principal Applicant : Finley, Christian

2013/1 - 2014/12

Principal Investigator

Trial of two combinations of radiation and chemotherapy in resectable cancer of the esophagus and stomach, Grant, Operating
 Clinical Research Project?: Yes
 Project Description: The objective of this study is to examine 2 treatment options. One group of patients will receive brachytherapy followed by chemotherapy before surgery while the other group will receive the same chemotherapy and the usual type of external radiation followed by surgery. After surgery the pathologist will determine the number of patients who have no cancer left ('complete pathologic response'). Secondary objectives will determine the time it takes for the tumor to come back, the location within the body where the cancer comes back, and differences in swallowing scores. Eligible patients will have esophageal cancer and be a candidate for curative surgery. Patients must be fit enough to tolerate the treatment and not have any other major medical problems. Patients with other types of cancers will be excluded. A total of 60 patients will be included and randomly assigned to a treatment option as explained above.

Funding Sources:

2013/1 - 2014/12 Juravinski Cancer Centre Foundation
 Fall Grants Competition
 Total Funding - 100,000 (Canadian dollar)
 Funding Competitive?: Yes

2011/11 - 2014/10

Co-applicant

18F-Sodium Fluoride PET imaging as a replacement for bone scintigraphy

Funding Sources:

2011/11 - 2014/10 Medical Imaging Trial NEtwork of Canada
 Theme 1: Oncology Imaging
 Total Funding - 697,655 (Canadian dollar)
 Funding Competitive?: Yes

Co-applicant : Goodbody, Anne; Pond, Greg; Valliant, John; Wong-Pack, William;

Principal Applicant : Gulenchyn, Karen

2012/3 - 2014/2

Principal Investigator

A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)., Contract
 Clinical Research Project?: Yes
 Project Description: A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC).

Funding Sources:

2012/3 - 2014/2 Synta Pharmaceuticals Inc. (USA)
 Lung Cancer Clinical Trials Program
 Total Funding - 100,000 (Canadian dollar)
 Funding Competitive?: No

| | |
|--|---|
| 2012/2 - 2014/1 Principal Investigator | <p>A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIB or IV Non-Small-Cell Lung Cancer, Contract Clinical Research Project?: Yes</p> <p>Funding Sources:</p> <p>2011/10 - 2013/9 Synta Pharmaceuticals Inc. (USA) Lung Cancer Clinical Trials Program Total Funding - 75,000 (Canadian dollar) Funding Competitive?: No</p> <p>Principal Investigator : Roaslyn Juergens</p> |
| 2012/1 - 2013/12 Principal Investigator | <p>A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV NSC Lung Cancer, Contract Clinical Research Project?: Yes</p> <p>Funding Sources:</p> <p>2012/1 - 2013/12 Bristol-Myers Squibb Canada Inc. Phase I clinical Trial with BMS Total Funding - 250,000 (Canadian dollar) Funding Competitive?: No</p> <p>Principal Investigator : Rosalyn Juergens</p> |
| 2011/1 - 2013/10 Principal Investigator | <p>A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene, Contract Clinical Research Project?: Yes</p> <p>Funding Sources:</p> <p>2011/10 - 2013/9 Astellas Pharma Canada, Inc. Lung Cancer Clinical Trials Program Total Funding - 86,430 (Canadian dollar) Funding Competitive?: No</p> |
| Completed [n=15] | |
| 2018/5 - 2020/4 Co-investigator | <p>Biomarker study in conjunction with a phase I/II clinical trial of Debio-1143 and avelumab</p> <p>Funding Sources:</p> <p>BioCanRX - Total Funding - 100,000 Funding Competitive?: Yes</p> |
| 2016/6 - 2019/5 Principal Applicant | <p>Oncolytic Virus Therapy in Cancer</p> <p>Funding Sources:</p> <p>2016/6 - 2019/5 BioCanRX - Total Funding - 120,000 (Canadian dollar) Funding Competitive?: Yes</p> |
| 2015/4 - 2016/3 Principal Applicant | <p>Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer, Contract</p> |

Clinical Research Project?: Yes

Funding Sources:

2015/4 - 2016/3 Merck Frosst Canada Inc
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: No

2012/1 - 2015/8
Principal Applicant

A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC), Contract
Clinical Research Project?: Yes

Funding Sources:

2012/1 - 2015/8 Bristol-Myers Squibb Canada Inc.
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: No

2008/10 - 2013/9
Co-investigator

SPORE in Lung Cancer

Funding Sources:

2008/10 - 2013/9 National Institutes of Health (NIH) (USA)
Epigenetics in Lung Cancer - P50 CA058184
Total Funding - 886,450 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Baylin, Stephen

2008/3 - 2013/2
Co-investigator

Phase 1 clinical trials of new anti-cancer targeted therapies, Grant
Clinical Research Project?: Yes

Funding Sources:

2008/3 - 2013/2 National Institutes of Health (NIH) (USA)
U01 Program Grant - UO1 CA70095
Total Funding - 2,950,000 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Carducci, Michael

2009/10 - 2012/9
Co-investigator

Phase II single-arm trial comparing the use of FLT PET to standard computed tomography to assess the treatment response of neoadjuvant docetaxel and cisplatin in stage IB-IIIa resectable NSCLC
Clinical Research Project?: Yes

Funding Sources:

2009/10 - 2012/9 National Institutes of Health (NIH) (USA)
Molecular Imaging Group and ARRA - N01-CM-27018
Total Funding - 1,219,480 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Wahl, Richard

2008/8 - 2012/7
Co-investigator

CHFR Methylation for Predicting Taxane Sensitivity in Lung and Esophageal Cancer, Grant, Operating
Clinical Research Project?: Yes
Project Description: These studies, for both neoadjuvant and palliative treatments, will determine the clinical utility of CHFR methylation to predict sensitivity of lung and esophageal cancer to taxanes.

Funding Sources:

2008/8 - 2012/7 National Institutes of Health (NIH) (USA)
 R33 CA127055-02
 Total Funding - 660,000 (United States dollar)
 Funding Competitive?: Yes

Principal Investigator : Herman, James

2007/7 - 2012/7 Targeting Epigenetic Changes in Metastatic Lung Cancer, Grant, Operating
 Principal Investigator Clinical Research Project?: Yes
 Project Description: The major goal of this research proposal is to test the efficacy of
 combined epigenetic targeting in patients with advanced, recurrent NSCLC using 5AC and
 MS-275

Funding Sources:

2007/7 - 2012/6 Flight Attendant Medical Research Institute
 Young Clinician Scientist Award
 Total Funding - 500,000 (United States dollar)
 Funding Competitive?: Yes

Principal Investigator : Rosalyn Juergens

2009/1 - 2010/12 Phase II Study of TAS-106 in Patients with Recurrent or Metastatic Head and Neck
 Principal Investigator Cancer Refractory to Platinum Based Chemotherapy, Contract

Funding Sources:

2009/1 - 2010/12 Taiho Pharmaceutical Co., Ltd.
 TAS 106
 Total Funding - 254,094 (Canadian dollar)
 Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2006/1 - 2010/12 Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response
 Principal Investigator Rate and Toxicity of Preoperative Combined Modality Paclitaxel, Cisplatin , ZD1839, and
 XRT Followed by Postop ZD1839, Contract

Funding Sources:

2006/1 - 2010/12 Astra Zeneca / US
 Astra Zeneca Unsolicited Letter of Intent and Proposal
 Total Funding - 250,000 (Canadian dollar)
 Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2008/11 - 2010/10 A Phase I Dose-escalation Study of OSI-906 and Erlotinib in Patients with Advanced Solid
 Principal Investigator Tumors, Contract

Funding Sources:

2008/11 - 2010/10 OSI Pharmaceuticals, Inc.
 Phase I Clinical Trial with OSI
 Total Funding - 320,912 (Canadian dollar)
 Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2008/7 - 2010/7 Epigenetics in Lung Cancer, Fellowship
 Principal Investigator

Funding Sources:

2008/7 - 2010/7 National Cancer Institute (USA)
 Lung Cancer SPORE Career Development Awardee
 Total Funding - 177,290 (United States dollar)
 Funding Competitive?: Yes

2005/7 - 2010/6 Epigenetics in Lung Cancer

Principal Investigator

Funding Sources:

2005/7 - 2010/6 National Institutes of Health (NIH) (USA)
 NIH Loan Repayment Grant Program
 Total Funding - 240,000 (United States dollar)
 Funding Competitive?: Yes

Principal Investigator : Rosalyn Juergens

2007/5 - 2010/4

Co-investigator

Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small Cell Lung Cancer, Grant, Operating
 Clinical Research Project?: Yes

Project Description: The major goal of this research proposal is to assess the safety, tolerability, pharmacokinetics, and efficacy of MS-275 and 5-Azacytidine in lung cancer patients.

Funding Sources:

2007/5 - 2010/4 National Institutes of Health (NIH) (USA)
 R21 - 1R21 CA126265-01A1
 Total Funding - 500,000 (United States dollar)
 Funding Competitive?: Yes

Principal Investigator : Rudin, Charles

[n=]

2024/1 - 2025/12

, Grant

Courses Taught

2014/07/02 -

2016/06/01

Supervisor, Oncology, McMaster University

Course Title: Interviewing, Examination, and Reasoning (half day)

Number of Students: 5

Lecture Hours Per Week: 5

Student/Postdoctoral Supervision**Post-doctorate [n=13]**

Co-Supervisor

Safwan Baksh (In Progress) , McMaster University

Student Degree Start Date: 2018/9

Project Description: Supervision of writing up case report in ALK + NSCLC

| | |
|--|--|
| Co-Supervisor | Aziz Abdul Al Farsi (Completed) , McMaster University Student Degree Start Date: 2015/7 Student Degree Received Date: 2017/6 Project Description: Co mentoring during Lung Cancer Clinical Fellowship Member of Masters of Health Sciences Thesis Committee |
| 2021/7 - 2023/6 Principal Supervisor | Yuchen Li, McMaster University Thesis/Project Title: Quality improvement in clinical trials conduct Present Position: Medical Oncology Resident |
| 2020/7 Principal Supervisor | Courtney Coschi, McMaster University Thesis/Project Title: Impact of translocation panel testing for never smokers with lung cancer in Hamilton, Ontario Present Position: Medical Oncology Resident |
| 2018/10 - 2022/6 Principal Supervisor | Michaela Febbraro (Completed) , McMaster University Student Degree Start Date: 2018/10 Student Degree Received Date: 2022/6 Thesis/Project Title: Implementation of clinical trials in rural Ontario Project Description: Supervision of Longitudinal Clinic Present Position: Medical Oncology Resident / Fellow |
| 2018/7 - 2020/6 Co-Supervisor | Samah AlRehaily (In Progress) , McMaster University Student Degree Start Date: 2018/7 Thesis/Project Title: Immunotherapy in Stage III NSCLC Project Description: Evaluation of appropriate use of octreotide scans in LHIN 4 Ontario Co-supervision of clinical fellowship Present Position: Clinical Fellow |
| 2017/7 - 2019/1 Co-Supervisor | Ying Wang (In Progress) , McMaster University Student Degree Start Date: 2017/7 Thesis/Project Title: Implementation of PD-L1 testing in Hamilton, Ontario including validation of cytology for assessment of PD-L1 status Project Description: Biomarker assessment in immunotherapy in NSCLC Present Position: Assistant Professor |
| 2016/7 - 2017/6 Co-Supervisor | Mohammed Al-Garni (Completed) , McMaster University Student Degree Start Date: 2016/7 Student Degree Received Date: 2017/6 Thesis/Project Title: Clinical fellowship in GI malignancies Project Description: Clinical fellowship co-supervisor Present Position: Assistant Professor - Saudi Arabia |
| 2014/10 - 2015/6 Principal Supervisor | Paul Barnfield (Completed) , McMaster University Student Degree Start Date: 2014/7 Student Degree Received Date: 2016/6 Thesis/Project Title: Next generation sequencing in non-small cell lung cancer Project Description: Economic analysis of multiplex testing in comparison to individual molecular testing in non-squamous non-small cell lung cancer Present Position: Assistant Professor |
| 2012/10 - 2013/6 Principal Supervisor | Brian Healy (Completed) , McMaster University Student Degree Start Date: 2013/7 Student Canadian Residency Status: Canadian Citizen Project Description: Medical Oncology Longitudinal Clinic Supervision |

| | |
|--|---|
| 2011/9 - 2012/11 Principal Supervisor | Vandermeer Rachel (Completed) , McMaster University Student Degree Start Date: 2012/4 Student Degree Received Date: 2013/6 Student Canadian Residency Status: Canadian Citizen Thesis/Project Title: Clinical supervisor for lung and esophageal cancer. Project on management of locally advanced esophageal cancer. Project Description: Randomized Trial of Chemotherapy followed by brachytherapy versus combined chemoradiotherapy in resectable esophageal cancer Present Position: Adjunct Assistant Professor |
| 2009/9 - 2011/6 Co-Supervisor | Roisin Connolly, (Completed) , Johns Hopkins Univ. Student Degree Start Date: 2009/7 Student Canadian Residency Status: Not Applicable Project Description: Double Epigenetic Therapy in Breast Cancer Present Position: Assistant Professor |
| 2009/7 - 2011/6 Co-Supervisor | John Wrangle (Completed) , Johns Hopkins Univ. Student Degree Start Date: 2009/7 Student Canadian Residency Status: Not Applicable Project Description: CHFR directed therapy in esophageal cancer Present Position: Fellow |

Staff Supervision

Mentoring Activities

| | |
|--------|--|
| 2015/1 | Internal Medicine Resident Mentor, McMaster University Number of Mentorees: 1 |
|--------|--|

Journal Review Activities

| | |
|-------------------|---|
| | Reviewer, The Open Clinical Cancer Journal Number of Works Reviewed / Refereed: 1 |
| | Reviewer, Clinical Cancer Research Number of Works Reviewed / Refereed: 1 |
| | Reviewer, Asian Pacific Journal of Oncology Number of Works Reviewed / Refereed: 1 |
| 2011/9 | Reviewer, Cancer Biology and Therapy Number of Works Reviewed / Refereed: 1 |
| 2010/8 | Reviewer, British Journal of Oncology Number of Works Reviewed / Refereed: 2 |
| 2009/6 | Reviewer, Biomed Central - Cancer Number of Works Reviewed / Refereed: 1 |
| 2009/2 | Reviewer, Journal of Clinical Oncology Number of Works Reviewed / Refereed: 2 |
| 2007/11 - 2011/12 | Reviewer, Annals of Surgical Oncology Number of Works Reviewed / Refereed: 4 |

2007/1 - 2009/3 Reviewer, American Journal of Medicine
Number of Works Reviewed / Refereed: 2

Conference Review Activities

2013/2 - 2013/4 Abstract Reviewer, 8th Annual Ontario Thoracic Cancer Conference, Blind, McMaster University
Number of Works Reviewed / Refereed: 26

Research Funding Application Assessment Activities

2013/5 - 2013/5 Committee Member, Juravinski Cancer Centre Foundation Spring Grant Review Panel, Funder, Academic Reviewer, Juravinski Cancer Centre Foundation
Number of Applications Assessed: 6

2009/6 - 2009/7 Committee Member, Department of Defense Grant Review Study Section, Funder, Academic Reviewer, Department of Defense
Number of Applications Assessed: 4

Event Participation

Invited Speaker, Shanghai Oriental Respiratory Forum, Conference, 2008/12 - 2008/12

Invited Speaker, 8th Annual Ontario Thoracic Cancer Conference, Conference, 2013/4 - 2013/4

Attendee, 10th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2010/2 - 2010/2
Overview of all agents in development for treatment of lung cancer

Attendee, New Investigator Workshop, Workshop, 2011/11 - 2011/11

Oral and poster presenter, Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Workshop, 2011/1 - 2011/1

Invited Speaker, 13th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2013/2 - 2013/2

Attendee, Accelerating Anticancer Agent Development and Validation Workshop, Workshop, 2009/6 - 2009/6
Intensive and interactive workshop in how to design effective strategies- from clinical trial initiatives, to enabling trials, to pivotal efficacy trials - leading to the development of new anticancer and prevention agents.

Invited Speaker, 12th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2012/2 - 2012/2

Attendee, Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Workshop, 2007/1 - 2007/1

Invited Speaker, 11th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2011/2 - 2011/2

Community and Volunteer Activities

2018/10 Physician Champion for Illuminight, Hamilton Health Sciences Corporation
Physician Champion for Fundraising Event

| | |
|---------|---|
| 2017/11 | Speaker at Lung Cancer Patient Forum, Lung Cancer Canada |
| 2017/11 | Patient / Caregiver Education Speaker, Wellwood |
| 2016/11 | Speaker at Lung Cancer Patient and Caregiver Summit, Lung Cancer Canada |
| 2016/6 | Executive Board Member, Lung Cancer Canada |
| 2016/6 | Chair of the Medical Advisory Committee, Lung Cancer Canada I have been invited to be a member of the Lung Cancer Canada Medical Advisory Panel |
| 2014/6 | Co-chair of Program Committee, Lung Cancer Canada 1) Develop and manage programs, projects and events; 2) Develop and manage the publication and distribution of newsletters, information sheets and other publications; |

International Collaboration Activities

| | |
|--------|--|
| 2011/1 | Collaborator, United States of America Ongoing collaboration with epigenetic research projects on AACR Stand Up to Cancer Grant |
|--------|--|

Committee Memberships

| | |
|------------------|---|
| 2018/3 | Committee Member, Esophageal Diagnostic Pathway Panel, Cancer Care Ontario |
| 2017/9 | Committee Member, Clinical Accelerator Scientific Leadership Committee, Cancer Research Institute |
| 2017/3 | Chair, Department of Clinical Trials Executive Committee, Juravinski Cancer Centre |
| 2016/6 | Chair, Medical Advisory Committee, Lung Cancer Canada, Lung Cancer Canada |
| 2015/7 | Committee Member, Medical Oncology Residency Education Committee, Juravinski Cancer Centre |
| 2015/6 | Committee Member, Disease Site Team Council, Juravinski Cancer Centre |
| 2013/2 | Chair, Lung Disease Site Team, Juravinski Cancer Centre |
| 2011/1 - 2016/12 | Committee Member, Translational Research Team - Management Committee, McMaster University |
| 2009/7 - 2010/12 | Committee Member, Johns Hopkins SKCC Education Committee, Johns Hopkins University |
| 2009/7 - 2010/12 | Co-chair, Visiting Professor Committee, Johns Hopkins University |
| 2007/7 - 2010/12 | Committee Member, U01 Internal Committee Member, Johns Hopkins University |
| 2005/7 - 2010/12 | Committee Member, Oncology Fellowship Advisory Committee, Johns Hopkins University |
| 2004/7 - 2010/12 | Committee Member, Oncology Critical Care Committee, Johns Hopkins Medical Institutions |
| 2006/7 - 2007/12 | Committee Member, Oncology Outpatient Department Advisory Committee, Johns Hopkins University |
| 2003/7 - 2004/6 | Committee Member, Core Committee on Physician Order Entry, Johns Hopkins University Role: Oncology fellowship representative |
| 2002/7 - 2003/6 | Committee Member, Performance Improvement Committee, Johns Hopkins Hospital |

| | |
|---------------|---|
| 2002/ - 2003/ | Committee Member, Steering Committee for Computerized Clinical Information Systems, Johns Hopkins Hospital Role: Medicine Residency Program Representative |
| 2001/ - 2003/ | Committee Member, Johns Hopkins Hospital Laboratory Advisory Committee, Johns Hopkins Hospital Role: Medicine Residency Program Representative |

Other Memberships

| | |
|--------|---|
| 2011/9 | Core Member, Escarpment Cancer Research Institute |
|--------|---|

Presentations

- (2020). Update on ATL-001. International Association for the Study of Lung Cancer: Targeted Therapy in Lung Cancer Meeting, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No
- (2020). Strategies for Treating Patients with Resistance to Immunotherapy. American Society of Clinical Oncology Annual Education Meeting, United States of America
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
- Matthew Hellman and Solange Peters. (2018). The New Era of Immune Therapy in Lung Cancer. World Congress on Lung Cancer, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
- (2018). Immune Checkpoint and Chemotherapy Combinations. World Congress on Lung Cancer, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
- (2018). New Era in Management of NSCLC. Employers Cancer Care Conference, Toronto, Canada
Main Audience: General Public
Invited?: Yes
- (2018). From Bedside to Bench and Back: The Story of Immunotherapy in Oncology. Juravinski Cancer Centre Student Research Day, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
- (2018). Update on Immunotherapy in Lung Cancer. Immuno-Oncology Summit, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
- (2018). Recognition and Management of Immuno-oncology Toxicities. Canadian Cancer Trials Group, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
- (2018). First Line Immunotherapy in Non-Small Cell Lung Cancer. World Congress on Lung Cancer, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

10. (2018). Patients and Physicians as Partners. Department of Oncology Student Research Day, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
11. (2018). First Line Immunotherapy in Lung Cancer. Best of Lung Cancer, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
12. (2017). Impact of Molecular testing in NSCLC. Precision Medicine Workshop, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
13. (2017). Biomarkers to Guide Immuno-oncology Use. Immuno-oncology Summit, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
14. (2017). Pseudoprogression in Immuno-oncology. National Consensus Meeting, Ottawa, Canada
Main Audience: Knowledge User
Invited?: Yes
15. (2017). PD-L1 Inhibition in Non-Small Cell Lung Cancer. World Congress on Lung Cancer, Vienna, Austria
Main Audience: Knowledge User
Invited?: Yes
16. (2017). Recognition and Management of Immuno-oncology Toxicities. C17 Annual Meeting, Vancouver, Canada
Main Audience: Knowledge User
Invited?: Yes
17. (2017). Innovations in Lung Cancer Treatments and Access to Therapies. Lung Cancer Canada Stakeholder Briefing, Vancouver, Canada
Main Audience: Decision Maker
Invited?: Yes
18. (2017). Immuno-oncology in Lung Cancer. Immuno-oncology Summit, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
19. (2017). Systemic Therapy in NSCLC - A New Hope. Lung Cancer Canada Patient Summit, Vancouver, Canada
Main Audience: General Public
Invited?: Yes
20. (2017). Immuno-oncology in GI Cancers. Immuno-oncology Summit, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
21. (2017). Management of Stage III NSCLC. Health Canada Presentation, Ottawa, Canada
Main Audience: Decision Maker
Invited?: Yes
22. Ellis, P. (2016). Developments in immuno-oncology: What does an internist need to know about releasing the brakes in the immune system?. McMaster University Internal Medicine Grand Rounds, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

23. (2016). Immunotherapy in Lung Cancer. British Columbia Cancer Agency Province Wide Rounds, Vancouver, Canada
Main Audience: Knowledge User
Invited?: Yes
24. (2016). Immunotherapy in Cancer. St. Michael's Annual Oncology Lectureship, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
25. (2016). Basics in Immuno-Oncology for GI Malignancies. 5th Multidisciplinary Annual Gastrointestinal Cancer Update, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
26. (2016). Immunotherapy in Cancer. Juravinski Hospital and Cancer Centre Oncology Inpatient Ward Education Day, Hamilton, Canada
Main Audience: General Public
Invited?: Yes
27. (2016). Update on Lung Cancer. Canadian Conference on Community Oncology, Whistler, Canada
Main Audience: Knowledge User
28. (2016). From Medical School to Oncology: The Long and Winding Road. Student Research Day, Winnipeg, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
29. (2016). Management of Gastric Cancer. Grand River Cancer Centre Regional Oncology Rounds, Kitchener, Canada
Main Audience: Knowledge User
Invited?: Yes
30. (2016). Biology of Stem Cells in Lung Cancer. 15th Annual Targeted Therapies of the Treatment of Lung Cancer., Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes
31. (2016). ASCO Lung Cancer Update. Regional Oncology Rounds, Hamilton, Canada
Main Audience: Knowledge User
32. (2016). Pathology Implications of Recent Treatment Advances in NSCLC. Hamilton Regional Pathology Meeting, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
33. (2016). Immunotherapy in Lung Cancer. Oncology Grand Rounds, Halifax, Canada
Main Audience: Knowledge User
34. (2016). Immunotherapy in GI Malignancies. LHIN 4 GI Symposium, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
35. Garth Nicholas, John Goffin, Scott Andrew Laurie, Andrew Robinson, Glenwood Goss, Neil Reaume, Mihaela Mates, Paul Wheatley-Price, Peter Ellis, Anna Tomiak, Richard Gregg. (2016). A phase Ib study of selumetinib in patients with previously untreated advanced/metastatic NSCLC who are receiving standard chemotherapy regimen: trial IND215 of the NCIC Clinical Trials Group. ASCO, Chicago, United States of America
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

36. (2016). Immunotherapy in Lung Cancer Cancer Care. Manitoba Provincial Oncology Rounds, Winnipeg, Canada
Main Audience: Knowledge User
Invited?: Yes
37. (2016). DNA Repair and Epigenetics in Cancer. Molecular Oncology for REsidents (MORE) Retreat, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
38. (2016). Immunotherapy in Lung Cancer. AMHOQ Annual Meeting, Quebec, Canada
Main Audience: Knowledge User
Invited?: Yes
39. (2016). Systemic Therapy in Gastric Cancer. Canadian Conference on Community Oncology, Whistler, Canada
Main Audience: Knowledge User
40. (2016). Immunotherapy in Lung Cancer. Cancer Care Manitoba Provincial Oncology Rounds, Winnipeg, Canada
Main Audience: Knowledge User
Invited?: Yes
41. (2016). Immunotherapy in Cancer. Central LHIN Humber River Oncology Nursing Day, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
42. (2016). Pulmonary Adenocarcinomas: An Update. Cancer Care Ontario Fall Webinar, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
43. (2016). Lung Cancer: Recent Advances, Practical Information and Recommendations. Immuno-Oncology Update, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
44. (2016). Immunotherapy in Lung Cancer Canadian Oncology Resident Education (CORE). Canadian Lung Cancer Conference, Canada
Main Audience: Knowledge User
45. (2015). Immunotherapy in Lung Cancer. Juravinski Cancer Centre Regional Oncology Rounds, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
46. (2015). Immunotherapy in Lung Cancer, Where are we now?. Canadian Lung Cancer Conference, Vancouver, Canada
Main Audience: Knowledge User
Invited?: Yes
47. (2015). Immunotherapy in Lung Cancer. Oncology Grand Rounds - Grand River Regional Cancer Centre, Kitchener, Canada
Main Audience: Knowledge User
48. (2015). Basics in Immuno-Oncology: From Bench to Bedside. Atlantic Canada Immuno-Oncology Symposium, Moncton, Canada
Main Audience: Knowledge User
Invited?: Yes

49. (2015). Chair of New Kinase Targets Session. World Conference on Lung Cancer, Denver, United States of America
Main Audience: Researcher
Invited?: Yes
50. (2015). Lung Cancer Immunotherapy. The Landscape in Canada Best of Lung Cancer Symposium, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
51. (2015). Immunotherapy in Lung Cancer. Canadian Cancer Research Conference, Montreal, Canada
Main Audience: Knowledge User
52. (2015). Future of Immunotherapy in Lung Cancer. Canadian Lung Cancer Conference, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
53. (2015). Chair of ALK and HSP90 Session on Targeted Therapies in Lung Cancer 15th Annual Targeted Therapies in the Treatment of Lung Cancer. 15th Annual Targeted Therapies in the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes
54. (2015). Immunotherapy: A new pillar of cancer treatment. Canadian Oncology Advocacy Meeting, Montreal, Canada
Main Audience: Knowledge User
Invited?: Yes
55. (2015). Immunotherapy in Lung Cancer. Ontario Thoracic Cancer Conference, Niagara-on-the-lake, Canada
Main Audience: Knowledge User
Invited?: Yes
56. Massey, N. (2015). Targeting the PD-1 / PD-L1 Axis: How Immunotherapies are Changing the Treatment of Non-Small Cell Lung Cancer. Canadian Association of Nursing in Oncology Annual Meeting, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes
57. (2014). Insulin-like growth factor inhibitors in lung cancer therapy. 14th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes
58. (2014). Epigenetic Therapy in Lung Cancer. 14th Annual Targeted Therapies in the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes
59. (2014). Double Epigenetic Therapy. 14th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes
60. (2014). Update on Lung Cancer. Juravinski Cancer Centre Chemotherapy Suite Nurses Education Rounds, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

61. (2014). Chemoradiation in esophageal cancer. Regional Oncology Rounds, Juravinski Cancer Centre, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
62. (2014). OSI-906 in Lung Cancer. 14th Annual Targeted Therapies in the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes
63. (2013). Targeted Therapies in Squamous Non-Small Cell Lung Cancer. 8th Annual Ontario Thoracic Cancer Conference, Niagara-on-the-Lake, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
64. (2013). Novel Therapies for Squamous Cell Lung Cancer. 8th Annual Ontario Thoracic Cancer Conference, Niagara-on-the-lake, Canada
Main Audience: Knowledge User
Invited?: Yes
65. Jonathan Bramson, PhD. (2012). Harnessing the Immune System in Cancer Treatment. Demystifying Medicine, McMaster University, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes
66. (2011). Analysis of a Phase II trial of 5-azacitidine(5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer.5th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy., San Diego, CA, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Broadcast Interviews

- | | |
|------------|---|
| 2017/11/12 | Lung Cancer in Never Smokers, The National, CTV |
| 2017/01/17 | Immunotherapy in Cancer, Hamilton Spectator |

Publications

Journal Articles

1. Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, Liu G. (2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.Curr Oncol.30(7): 6559-6574.
<http://dx.doi.org/10.3390/currncol30070481>.
Co-Author
Published,
Refereed?: Yes, Open Access?: No
2. Melosky BL, Leighl NB, Dawe D, Blais N, Wheatley-Price PF, Chu QS, Juergens RA, Ellis PM, Sun A, Schellenberg D, Ionescu DN, Cheema PK. (2023). Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.Curr Oncol.30(7): 6289-6315.
<http://dx.doi.org/10.3390/currncol30070465>.
Published,
Refereed?: Yes, Open Access?: No

3. Coschi CH, Juergens RA. (2023). Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response. *Curr Oncol*.31(1): 1-23.
<http://dx.doi.org/10.3390/curroncol31010001>
 Last Author
 Published,
 Refereed?: Yes, Open Access?: No
 Number of Contributors: 2
4. Esfahanian N, Chan SWS, Zhan LJ, Brown MC, Khan K, Lee J, Balaratnam K, Yan E, Parker J, Garcia-Pardo M, Barghout SH, Eng L, Bradbury PA, Shepherd FA, Leighl NB, Sacher AG, Snow S, Juergens R, Liu G. (2023). Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. *Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence*.37(100774)
<http://dx.doi.org/10.1016/j.ctarc.2023.100774>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: No
 Number of Contributors: 19
5. Febbraro M, Kazemi G, Juergens R, Pond GR. (2023). Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology-A National Questionnaire. *Curr Oncol*.30(8): 7627-7637.
<http://dx.doi.org/10.3390/curroncol30080553>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: No
6. Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. (2023). ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. *Nat Med*.29(10): 2559-2569..
<http://dx.doi.org/10.1038/s41591-023-02598-9>
 Published,
 Refereed?: Yes, Open Access?: No
7. Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. (2023). Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. *Oncology*. 37(4): 176-183..
<http://dx.doi.org/10.46883/2023.25920992>
 Co-Author
 Published, Williston Park,
 Refereed?: Yes, Open Access?: No
8. Chan SWS, Shukla R, Ramsay J, McWhirter E, Barnfield P, Juergens RA. (2023). Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. *Curr Oncol*.30(5): 4527-4537.
<http://dx.doi.org/10.3390/curroncol30050342>
 Last Author
 Published,
 Refereed?: Yes, Open Access?: No

9. Sayeda S, Naqvi A, Begum H, Juergens RA, Finley C, Coschi CH, Cutz JC, Bonert M. (2023). Prevalence of Thyroid Transcription Factor-1 (TTF-1)-Negative Small Cell Carcinoma and Napsin A Positivity in Small Cell Carcinoma in a Cross-Sectional Study of Lung Core Biopsies.Cureus. 15(4): e37015.
<http://dx.doi.org/10.7759/cureus.37015>
Co-Author
Published,
Refereed?: Yes, Open Access?: No
10. Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, Leighl NB, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. (2023). Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.Curr Oncol.30(7): 6473-6496.
<http://dx.doi.org/10.3390/curroncol30070476>
Co-Author
Published,
Refereed?: Yes, Open Access?: No
11. Li Y, Juergens RA, Finley C, Swaminath A. (2023). Current and Future Treatment Options in the Management of Stage III NSCLC.J Thorac Oncol.18(11): 1478-1491.
<http://dx.doi.org/10.1016/j.jtho.2023.08.011>
Co-Author,
Refereed?: Yes, Open Access?: No
12. Bonert M, Berzins A, Begum H, Schittenhelm J, Lu JQ, Juergens RA, Swaminath A, Cutz JC, Naqvi AH. (2023). Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history.PLoS One.18(11): e0294154.
<http://dx.doi.org/10.1371/journal.pone.0294154>
Published,
Refereed?: Yes, Open Access?: No
13. Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N. (2022). BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.JTO Clin Res Rep.3(11): 100400.
<http://dx.doi.org/10.1016/j.jtocrr.2022.100400>
Published,
Refereed?: Yes, Open Access?: No
14. Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Melosky B, Shepherd FA, Cohen V, Wheatley-Price P, Vandermeer R, Li JJ, Fernandes R, Shokoohi A, Lanman RB, Leighl NB. (2022). The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.Ther Adv Med Oncol.14: 17588359221112696.
<http://dx.doi.org/10.1177/17588359221112696>
Co-Author
Published,
Refereed?: Yes, Open Access?: No
15. Husereau D, Sullivan T, Feilotter HE, Gomes MM, Juergens R, Sheffield BS, Kassam S, Stockley TL, Jacobs P. (2022). Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems.J Med Econ.25(1): 993-1004..
<http://dx.doi.org/10.1080/13696998.2022.2101807>
Published,
Refereed?: Yes, Open Access?: No

16. Lee Y, Samarasinghe Y, Lee MH, Thiru L, Shargall Y, Finley C, Hanna W, Levine O, Juergens R, Agzarian, J. (2022). Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis. . *Annals of Surgery*. 275(1): 91-98.
Published,
Refereed?: Yes, Open Access?: No
17. Febbraro M, Gheware A, Kennedy T, Jain D, de Moraes FY, Juergens R. (2022). Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer.*Am Soc Clin Oncol Educ Book*.42: 1-7.
Published,
Refereed?: Yes, Open Access?: No
18. Bonert M, Zafar U, Williams P, El-Shinnawy I, Juergens RA, Naqvi A, Cutz JC, Finley C, Major P, Kapoor A. (2022). Physician and Surgeon Communication Assessed via the Pathology Requisition in a Regional Laboratory Over Ten Years.*Cureus*.14(8): e27714.
<http://dx.doi.org/10.7759/cureus.27714>.
Published,
19. Ramadan S, Quan K, Schnarr K, Juergens RA, Hotte SJ, Mukherjee SD, Kapoor A, Meyers BM, Swaminath A. (2022). Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.*Acta Oncol*.61(6): 705-713..
<http://dx.doi.org/10.1080/0284186X.2022.2063067>
Published,
Refereed?: Yes, Open Access?: No
20. Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. (2021). The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. . *Ther Adv Med Oncol*.11: 1.
Published,
Refereed?: Yes, Open Access?: No
21. Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, Liu G, Card PB, Chu Q. (2021). The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.*Lung Cancer*. 160: 136-151.
Published,
Refereed?: Yes, Open Access?: No
22. Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U. (2021). Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.*Journal of Nuclear Medicine*. 62(10): 1406-1414.
Published,
Refereed?: Yes, Open Access?: No
23. Seow H, Tanuseputro P, Barbera L, Earle CC, Guthrie DM, Isenberg SR, Juergens RA, Myers J, Brouwers M, Tibebe S, Sutradhar R. (2021). Development and validation of a prediction model of poor performance status and severe symptoms over time in cancer patients (PROVIEW+).*Palliative Medicine*. 35(9): 1713-1723.
Published,
Refereed?: Yes, Open Access?: No
24. Bonert M, Zafar U, Maung R, El-Shinnawy I, Kak I, Cutz JC, Naqvi A, Juergens RA, Finley C, Salama S, Major P, Kapoor A. (2021). Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports.*PLoS One*. 16(6): 1.
Published,
Refereed?: Yes, Open Access?: No

25. Coschi CH, Juergens RA. (2021). The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. *Current Oncology*. 28(6): 4392-4407.
Published,
Refereed?: Yes, Open Access?: No
26. Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M. (2021). Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada. *Lung Cancer*. 157: 40-47.
Published,
Refereed?: Yes, Open Access?: No
27. Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. (2021). The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. *Ther Adv Med Oncol*. 13: 17588359211056306.
<http://dx.doi.org/10.1177/17588359211056306>.
Published,
Refereed?: Yes, Open Access?: No
28. Cheema PK, Banerji SO, Blais N, Chu QS, Desmeules P, Juergens RA, Leighl NB, Sheffield BS, Wheatley-Price PF, Melosky BL. (2021). Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. *Curr Oncol*. 28(6): 4552-4576..
<http://dx.doi.org/10.3390/curroncol28060386>.
Published,
Refereed?: Yes, Open Access?: No
29. Melosky B , Banerji S , Blais N , Chu Q , Juergens R , Leighl NB , Liu G , Cheema P. (2020). Canadian consensus: a new systemic treatment algorithm for advanced *EGFR*- mutated non-small-cell lung cancer. *Current oncology*. 27(2): e146-e155.
Published,
30. Nehra J , Bradbury PA , Ellis PM , Laskin J , Kollmannsberger C , Hao D , Juergens RA , Goss G , Wheatley-Price P , Hotte SJ , Gelmon K , Tinker AV , Brown-Walker P , Gauthier I , Tu D , Song X , Khan A , Seymour L , Smoragiewicz M. (2020). A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. *Investigational new drugs*. 38(5): 1442-1447.
Published,
31. Melosky B , Cheema PK , Brade A , McLeod D , Liu G , Price PW , Jao K , Schellenberg DD , Juergens R , Leighl N , Chu Q. (2020). Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. *The oncologist*. 25(1): 64-77.
Published,
32. Juergens RA , Hao D , Ellis PM , Tu D , Mates M , Kollmannsberger C , Bradbury PA , Tehfe M , Wheatley-Price P , Robinson A , Bebb G , Laskin J , Goffin J , Hilton J , Tomiak A , Hotte S , Goss GD , Brown-Walker P , Sun X , Tsao MS , Cabanero M , Gauthier I , Song X , Dennis PA , Seymour LK , Smoragiewicz M , Laurie SA. (2020). A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. *Lung cancer (Amsterdam, Netherlands)*. 143: 1-11.
Published,
33. Dawe DE , Harlos CH , Juergens RA. (2020). Immuno-oncology-the new paradigm of lung cancer treatment. *Current oncology (Toronto, Ont.)*. 27(Suppl 2): S78-S86.
Published,

34. Catenacci DVT , Kang YK , Park H , Uronis HE , Lee KW , Ng MCH , Enzinger PC , Park SH , Gold PJ , Lacy J , Hochster HS , Oh SC , Kim YH , Marrone KA , Kelly RJ , Juergens RA , Kim JG , Bendell JC , Alcindor T , Sym SJ , Song EK , Chee CE , Chao Y , Kim S , Lockhart AC , Knutson KL , Yen J , Franovic A , Nordstrom JL , Li D , Wigginton J , Davidson-Moncada JK , Rosales MK , Bang YJ , CP-MGAH22-5 Study Group. (2020). Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. *The Lancet. Oncology*. 21(8): 1066-1076.
Published,
35. Lu Z , Zou J , Li S , Topper MJ , Tao Y , Zhang H , Jiao X , Xie W , Kong X , Vaz M , Li H , Cai Y , Xia L , Huang P , Rodgers K , Lee B , Riemer JB , Day CP , Yen RC , Cui Y , Wang Y , Wang Y , Zhang W , Easwaran H , Hulbert A , Kim K , Juergens RA , Yang SC , Battafarano RJ , Bush EL , Broderick SR , Cattaneo SM , Brahmer JR , Rudin CM , Wrangle J , Mei Y , Kim YJ , Zhang B , Wang KK , Forde PM , Margolick JB , Nelkin BD , Zahnow CA , Pardoll DM , Housseau F , Baylin SB , Shen L , Brock MV. (2020). Epigenetic therapy inhibits metastases by disrupting premetastatic niches. *Nature*. 579(7798): 284-290.
Published,
36. Colomer-Lahiguera S , Bryant-Lukosius D , Rietkoetter S , Martelli L , Ribi K , Fitzpatrick-Lewis D , Sherifali D , Orcurto A , Juergens R , Eicher M. (2020). Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review. *Journal of patient-reported outcomes*. 4(1): 58.
Published,
37. Melosky B , Juergens R , Hirsh V , McLeod D , Leighl N , Tsao MS , Card PB , Chu Q. (2020). Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. *The oncologist*. 25(1): 64-77.
Published,
38. Seow H , Tanuseputro P , Barbera L , Earle C , Guthrie D , Isenberg S , Juergens R , Myers J , Brouwers M , Sutradhar R. (2020). Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer. *JAMA network open*. 3(4): e201768.
Published,
39. Laurie SA , Banerji S , Blais N , Brule S , Cheema PK , Cheung P , Daaboul N , Hao D , Hirsh V , Juergens R , Laskin J , Leighl N , MacRae R , Nicholas G , Roberge D , Rothenstein J , Stewart DJ , Tsao MS. (2019). Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. *Current oncology (Toronto, Ont.)*. 26(1): e81-e93.
Published,
40. Goffin JR , Nicholas G , Mates M , Tu D , Chen E , Laurie SA , Juergens R , Robinson A , Goss G , Reaume M , Sun S , Christink K , Maize C , MacFarlan S , Sun X , Ritter H , Seymour L , Bradbury PA. (2019). Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. *Invest New Drugs*. 37(3): 498-506.
Published,
Refereed?: Yes, Open Access?: No
41. Wang Y , Van Dam A , Slaven M , Ellis KJ , Goffin JR , Juergens RA , Ellis PM. (2019). Resource use in the last three months of life by lung cancer patients in southern Ontario. *Current oncology (Toronto, Ont.)*. 26(4): 247-252.
Published,
42. Melosky B , Juergens R , McLeod D , Leighl N , Brade A , Card PB , Chu Q. (2019). Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 134: 259-267.
Published,

43. Melosky B , Chu Q , Juergens RA , Leighl N , Ionescu D , Tsao MS , McLeod D , Hirsh V. (2018). Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.Cancer treatment reviews. 65: 65-77.
Published,
44. Juergens RA , Mariano C , Jolivet J , Finn N , Rothenstein J , Reaume MN , Faghih A , Labbé C , Owen S , Shepherd FA , Villeneuve J , Romeyer F , Pettersson F , Butts C. (2018). Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.Current oncology (Toronto, Ont.). 25(6): 384-392.
Published,
45. Gettinger S , Hellmann MD , Chow LQM , Borghaei H , Antonia S , Brahmer JR , Goldman JW , Gerber DE , Juergens RA , Shepherd FA , Laurie SA , Young TC , Li X , Geese WJ , Rizvi N. (2018). Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(9): 1363-1372.
Published,
46. Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. (2018). Standardizing biomarker testing for Canadian patients with advanced lung cancer.Curr Oncol. 25(1): 73-82.
Published,
47. Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. (2018). Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.J Thorac Oncol. 2018(13): 9.
Published,
48. Melosky B , Cheema P , Agulnik J , Albadine R , Bebb DG , Blais N , Burkes R , Butts C , Card PB , Chan AMY , Hirsh V , Ionescu DN , Juergens R , Morzycki W , Poonja Z , Sangha R , Tehfe M , Tsao MS , Vincent M , Xu Z , Liu G. (2018). Canadian consensus: a new systemic treatment algorithm for advanced *EGFR*- mutated non-small-cell lung cancer. Current oncology (Toronto, Ont.). 25(5): 317-328.
Published,
49. Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara Kuruvilla M, Razak AR, Hansen AR. (2017). Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.Cancer Treat Rev.54: 43-57.
Published,
50. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA. (2017). First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.N Engl J Med.376(25): 2415-2426.
Published,
Refereed?: Yes, Open Access?: No
51. Nguyen NA, Isfahanian N, Pond G, Hanna W, Cutz JC, Wright J, Swaminath A, Shargall Y, Chow T, Wierzbicki M, Okawara G, Quan K, Finley C, Juergens R, Tsakiridis T. (2017). A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).Clin Lung Cancer. 18(4): 436-440.
Published,
52. Iaforla MAJ and Juergens RA. (2017). Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.Front Oncol. 7(67): 1-14.
Published,

53. Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott N. Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal E. Ready, David E. Gerber, Laura Q. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott J. Antonia. (2017). Nivolumab plus Ipilimumab First-Line in Advanced Non-Small-Cell Lung Cancer. *Lancet Oncol.* 18(1): 31-41. Published,
54. Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. (2017). Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. *Curr Oncol.* 24(2): 111-119. Published,
Refereed?: Yes, Open Access?: No
55. Nadler M, Bainbridge D, Tomasone J, Cheifetz O, Juergens RA, Sussman J. (2017). Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitators. *Support Care Cancer.* 25(7): 2297-2304. Published,
56. Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V. (2016). Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. *Curr Oncol.* 23(3): 196-200. Co-Author
Published,
Refereed?: Yes
57. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD. (2016). Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol.* 34(25): 2980-2987. Co-Author
Published,
Refereed?: Yes
58. Yiu KC, Juergens RA, Swaminath A. (2016). Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey. *Clin Oncol (R Coll Radiol).* 28(10): 667. Published,
59. Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. (2016). Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. *Clin Lung Cancer.* 8(16): S1525, 30187-5. Co-Author
Published,
Refereed?: Yes
Number of Contributors: 19
60. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia. (2016). Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol.* 34(25): 2969-2979. Published,
Refereed?: Yes
61. Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM. (2016). Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 22(12): 2897-2907. Published,

62. Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. (2016). Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. *J Clin Oncol.* 34(14): 1676-88.
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes
63. Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. (2016). Imaging Biomarkers in Immunotherapy. *Biomark Cancer.* 8(Suppl 2): 1-13.
First Listed Author
Published,
Refereed?: Yes, Open Access?: No
64. Juergens RA , Rudin CM. (2013). Aberrant epigenetic regulation. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2013,
65. Halmos B , Jia Y , Bokar JA , Fu P , Adelstein DJ , Juergens R , Rodal MB , Dowlati A. (2013). A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. *Investigational new drugs.* ,
66. Tsao A , Hui EP , Juergens R , Marur S , Huat TE , Cher GB , Hong RL , Hong WK , Chan AT. (2013). Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. *Cancer medicine.* 2(3),
67. Rudin CM , Brahmer JR , Juergens RA , Hann CL , Ettinger DS , Sebree R , Smith R , Aftab BT , Huang P , Liu JO. (2013). Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* 8(5),
68. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancracking W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB. (2013). Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. *Oncotarget.* 4(11),
69. Levine MN , Juergens R. (2012). Method to our madness or madness in our methods? Pitfalls in trial methodology. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 30(17),
70. Juergens RA , Wrangle J , Vendetti FP , Murphy SC , Zhao M , Coleman B , Sebree R , Rodgers K , Hooker CM , Franco N , Lee B , Tsai S , Delgado IE , Rudek MA , Belinsky SA , Herman JG , Baylin SB , Brock MV , Rudin CM. (2011). Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. *Cancer discovery.* 1(7),
71. Rudin CM , Mauer A , Smakal M , Juergens R , Spelda S , Wertheim M , Coates A , McKeegan E , Ansell P , Zhou X , Qian J , Pradhan R , Dowell B , Krivoshik A , Gordon G. (2011). Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 29(8),
72. Paik PK , Rudin CM , Pietanza MC , Brown A , Rizvi NA , Takebe N , Travis W , James L , Ginsberg MS , Juergens R , Markus S , Tyson L , Subzwari S , Kris MG , Krug LM. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. *Lung cancer (Amsterdam, Netherlands).* 74(3),
73. Paik PK , Rudin CM , Brown A , Rizvi NA , Takebe N , Travis W , James L , Ginsberg MS , Juergens R , Markus S , Tyson L , Subzwari S , Kris MG , Krug LM. (2010). A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. *Cancer chemotherapy and pharmacology.* 66(6), , Open Access?: Yes

74. Burns TF , Juergens RA. (2010). Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. *Oncology* (Williston Park, N.Y.). 24(13),

Book Chapters

1. Juergens, RA. (2011). Take Action: Comprehensive Treatment Options in Lung Cancer. J. Klamerus MD, J. Brahmer MD, and D. Ettinger MD. *The Johns Hopkins Guide to Lung Cancer*. : 23-62.
First Listed Author
Published, Jones and Bartlett Learning, United States of America
Number of Contributors: 1

Thesis/Dissertation

1. Targeting Epigenetic Changes in Non-Small Cell Lung Cancer. (2012). Johns Hopkins University. Doctorate. Supervisor: Charles Rudin, MD PhD

Reports

- [1.](#) Co-Author. Normand Blais, Quincy Chu, Peter Ellis, Meredith Giuliani, Diana Ionescu, Rosalyn Juergens, Stephen Lam, Janessa Laskin, Natasha Leighl, Donna Maziak, Jeffrey Rothenstein, Yee Ung, Zhaolin Xu. (2015). 2015 Faces of Lung Cancer Report. 20. Lung Cancer Canada.
Number of Contributors: 24
- [2.](#) Co-Author. Paul Wheatley-Price, Normand Blais, Quincy Chu, Meredith Giuliani, Cheryl Ho, Diana Ionescu, Rosalyn Juergens, Stephen Lam, Natasha Leighl, Donna Maziak, Jeffrey Rothenstein, Yee Ung, Zhaolin Xu. (2014). 2014 Faces of Lung Cancer Report - Fighting Disease, Fighting Disparity. 43. Lung Cancer Canada.
Number of Contributors: 12

Online Resources

- [1.](#) First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy. (2013).
Editors: J. West
- [2.](#) First Listed Author. Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?. (2013).
Editors: Jack West, MD
- [3.](#) First Listed Author. R.A Juergens. Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer. (2013).
Editors: J. West
- [4.](#) First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?. (2013).
Editors: J. West
- [5.](#) First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?". (2013).
Editors: J. West
- [6.](#) First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?. (2013).
Editors: J. West

- [7.](#) R. A. Juergens. Dr. Rosalyn Juergens on “My Approach to Maintenance Therapy for Advanced NSCLC”. (2013).
Editors: J. West
- [8.](#) First Listed Author. R.A Juergens. Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC. (2013).
Editors: J. West
- [9.](#) Co-Author. D. Ettinger, J. West, R.A. Juergens. Today’s Patient in Non–Small-Cell Lung Cancer: Does Histology Make A Difference? An Interactive E-Platform Featuring Patient Simulations. (2010).
Number of Contributors: 3
Editors: D. Ettinger
Description / Contribution Value: An Interactive E-Platform Featuring Patient Simulations
- [10.](#) Last Author. Daniel Laheru, MD; Anthony Boutros El-Khoueiry, MD; Nilofer Azad, MD; Rosalyn Juergens, MD. Expert Perspectives: GI Cancers Update, 2010. (2010).
Number of Contributors: 4
Editors: D. Laheru

Conference Publications

1. Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD. CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. IASLC 2016 Chicago Multidisciplinary Symposium in Thoracic Oncology., Chicago, United States of America, Poster
Refereed?: Yes, Invited?: No
2. Dimas Yusuf, Jenny J. Ko, Hyokeun Cho, Corey Sheremeto, Ying Wang, Rosalyn A. Juergens, Peter Michael Ellis, Alkarim Billawala, Amin Kay, Swati Kulkarni, Tarek A. Elfiki, Rasna Gupta, Krista Naccarato, Alex Pennetti, Devalben Patel, Elliot Charles Smith, Ryan Walton, Manjusha Hurry, Geoffrey Liu, Winson Y. Cheung. Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. American Society of Clinical Oncology / Society for Immunotherapy in Cancer Meeting., Orlando, United States of America, Conference Date: 2020/2
Poster
Refereed?: Yes, Invited?: No
3. Jason Agulnik, Jennifer H. Law, Rosalyn Juergens, Janessa Laskin, Scott Laurie, Desiree Hao, Doreen Ezeife, Lisa Le, Lesli A. Kiedrowski, Richard B. Lanman, Natasha Leighl. Defining VALUE: Routine liquid biopsy in NSCLC diagnosis - a Canadian trial in progress. AACR Special Conference on Advances in Liquid Biopsies., Miami, United States of America, Conference Date: 2020/1
Poster
Refereed?: Yes, Invited?: No
4. Michael Bonert, Asghar Naqvi, Christian Finley, Rosalyn Juergens, Phillip Williams, Pierre Major, Anil Kapoor. Communication with pathology evaluated via the pathology requisition using 396,033 pathology reports. European Congress of Pathology., Nice, France, Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: No

5. R. Wong, D. Laidley, S. D. Myrehaug, J. Brierley, R. Juergens, I. W. T. Yeung, S. Breen, B. Driscoll, A. Shessel, T. Farncombe, K. Zukotynski, R. Stodilka, C. B. Caldwell, Z. Liu, J. Valliant, J. McCann, U. Metser, R. Mohan, J. M. Beauregard, and D. A. Jaffray. Quantifying Renal And Tumor Doses With Individualized Dosimetry In 177Lu DOTATATE Therapy – What Difference Does It Make?. American Society for Radiation Oncology., Chicago, United States of America,
Conference Date: 2019/9
Poster
Refereed?: Yes, Invited?: No

6. Rosalyn Anne Juergens, Peter M Ellis, Dongsheng Tu, Desiree Hao, Scott A Laurie, Mihaela Mates, Glenwood D. Goss, John Goffin, Penelope A Bradbury, Mustapha Tehfe, Christian Kollmansberger, Pamela Brown-Walker, Martin Smoragiewicz, Ming Sound Tsao, Lesley Seymour. Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226. World Congress on Lung Cancer, Barcelona, Spain,
Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: No

7. Arani Sathiyapalan, Ying Wang, , Martin Butcher, Asghar Naqvi, Jean-Claude Cutz, Rosalyn Anne Juergens. Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer. World Congress on Lung Cancer, Barcelona, Spain,
Conference Date: 2019/9
Poster
Refereed?: Yes, Invited?: No

8. Michael Bonert, Jean-Claude Cutz, Christian Finley, Ihab El-Shinnawy, Samih Salama, Gabriella Gohla, Salem Alowami, Dusan Lukic, Farnoosh Tayyari, Rosalyn Juergens, Asghar Naqvi. Visceral Pleural Invasion by Tumour Size, Cancer Type and Pathologist in 1,560 Resections. European Congress of Pathology, Nice, France,
Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: No

9. D Hao; P M Ellis; S A Laurie; R A Juergens; M Mates; P A Bradbury; M Tsao; M Tehfe; C K Kollmannsberger; J R Goffin; P Wheatley-Price; J Hilton; A G Robinson; P Brown-Walker; D Tu; M Smoragiewicz; L K Seymour. Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy. European Society of Medical Oncology Annual Meeting, Barcelona, Spain,
Conference Date: 2019/9
Poster
Refereed?: Yes, Invited?: No

10. Rosalyn A. Juergens, Katherine A. Zukotynski, Daniel Juneau, Lily Krnezich, Ryan Simms, John Forbes, Eric S. Burak, John Valliant, Lauren Stafford, Thomas Armor, Istvan Molnar, Fred Saad. A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. American Society of Clinical Oncology Annual Meeting, Chicago, United States of America,
Conference Date: 2019/6
Poster
Refereed?: Yes, Invited?: No

11. Rosalyn A. Juergens, Quincy S. Chu, Daniel John Renouf, Scott Andrew Laurie, Daniela Purcea, Elaine McWhirter, Diane Arndt, Karen A. Gelmon, John Hilton, Bruno Gavillet, Peter Michael Ellis, Michael B. Sawyer, Christian K. Kollmannsberger, Natalie Andrews Wright, Elisabeth Rouits, Frank Brichory, Gregoire Vuagniaux, Sergio A. Szyldergemajn, Glenwood Goss. A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. American Society of Clinical Oncology Annual Meeting, Chicago, United States of America,
Conference Date: 2019/6
Poster
Refereed?: Yes, Invited?: No
12. Martin Früh, Osama E. Rahma, Russell K. Pachynski, Julien Mazières, Jerome Goldschmidt, Jr, Thanh G. N. Ton, Shivani K. Mhatre, Ching-Yi Chuo, Jorge Martinalbo, Jessica Davies, Rosalyn Juergens. Characteristics of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Receiving Atezolizumab Monotherapy in US Clinical Practice. European Lung Cancer Conference., Geneva, Switzerland,
Conference Date: 2019/4
Poster
Refereed?: Yes, Invited?: No
13. S Colomer-Lahiguera; D Bryant-Lukosius; S Rietkoetter; L Martelli; K Ribí; A Orcurto; R Juergens; M Eicher. The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review. European Society of Medical Oncology Annual Meeting., Munich, Germany,
Conference Date: 2018/10
Poster
Refereed?: Yes, Invited?: No
14. Doreen Anuli Ezeife | Author(s): Jason S Agulnik, Rosalyn Juergens, Janessa Laskin, Scott A. Laurie, Lisa Le, Desiree Hao, Gwyn Bebb, Jennifer H Law, Stan Skrzypczak, Daniela Juri, Richard B Lanman, Natasha B Leighl. Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE). World Congress on Lung Cancer, Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No
15. Parneet Kaur Cheema, Geoffrey Liu, Ronald Burkes, Scott Owen, Joanne Yu, Desiree Hao, Jeffrey Rothenstein, Simon Martel, Mussawar Iqbal, Rosalyn Juergens, Wendy Lam, Janessa Laskin. Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis. World Congress on Lung Cancer., Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No
16. Scott J Antonia, Scott N. Gettinger, Hossein Borghaei, Jonathan W. Goldman, Julie R. Brahmer, Neal E. Ready, David E Gerber, Laura Q Chow, Rosalyn Juergens, Scott A. Laurie, Frances A Shepherd, Xuemei Li, Ang Li, William J. Geese, Matthew D. Hellmann. Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. World Congress on Lung Cancer., Toronto, Canada,
Conference Date: 2018/9
Abstract
Refereed?: Yes, Invited?: No
17. Ying Wang, Martin Butcher, Asghar Naqvi, Jean-Claude Cutz, Rosalyn Juergens. Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer. World Congress on Lung Cancer., Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No

18. 17. Rosalyn Juergens | Author(s): Martin Butcher, Asghar Naqvi, Jean-Claude Cutz, Michael Bonert.Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region.World Congress on Lung Cancer, Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No
19. C. Fahim, J. Agzarian, W. Hanna, R. Juergens, Y. Shargall, M. Simunovic.High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center.European Lung Cancer Conference., Geneva, Switzerland,
Conference Date: 2018/4
Poster
Refereed?: Yes, Invited?: No
20. R. Juergens, Q. Chu, J. Rothenstein, F. De Angelis, S. Banerji, K. Marquis, D. Sauciu, P. Begin, N. Finn, V. Hirsh, A. Faghih, J. Yun, A. Li, A. Acevedo, L. Musallam, P. Cheema.CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients.World Congress on Lung Cancer, Yokohama, Japan,
Conference Date: 2017/11
Poster
Refereed?: Yes, Invited?: No
21. R. Juergens, D. Hao, S. Laurie, P. Ellis, M. Mates, P. Bradbury, M. Tehfe, C. Kollmannsberger, A. Arnold, J. Goffin, P. Wheatley-Price, J. Hilton, A. Robinson, D. Tu, P. Brown-Walker, L. Seymour.Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226.World Congress on Lung Cancer, Yokohama, Japan,
Conference Date: 2017/11
Abstract
Refereed?: Yes, Invited?: No
22. R. Juergens, M. Hellmann, J. Brahmer, H. Borghaei, S. Gettinger, L. Chow, D. Gerber, S. Laurie, J. Goldman, F. Shepherd, W. Geese, T. Young, X. Li, S. Antonia.First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update.World Congress on Lung Cancer, Yokohama, Japan,
Conference Date: 2017/11
Abstract
Refereed?: Yes, Invited?: No
23. Q.S-C. Chu; C. van Herpen; N.B. Leighl; B. Markman; S. Clarke; R.A. Juergens; P. Basciano; D. Lathers; S. Tannenbaum-Dvir; K. Urbanska; G. Kollia; C. Darby; D. Williams; G. Kolaitis; N. Ready.Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC).European Society of Medical Oncology Annual Meeting., Madrid, Spain,
Conference Date: 2017/9
Poster
Refereed?: Yes, Invited?: No
24. Rosalyn Juergens, Desiree Hao, Scott Laurie, Mihaela Mates, Mustapha Tehfe, Penelope Bradbury, Christian Kollmannsberger, Peter Ellis, John Hilton, Pamela Brown-Walker, Lesley Seymour.Cisplatin/ Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226.World Congress on Lung Cancer, Vienna, Austria,
Conference Date: 2016/12
Abstract
Refereed?: Yes, Invited?: No

25. Scott Gettinger, Naiyer Rizvi, Laura Chow, Hossein Borghaei, Julie Brahmer, Frances Shepherd, Neal Ready, David Gerber, Scott Antonia, Jonathan W. Goldman, Rosalyn Juergens, William Geese, Tina Young, Xuemei Li, Matthew Hellmann..First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012.World Congress on Lung Cancer, Vienna, Austria,
Conference Date: 2016/12
Poster
Refereed?: Yes, Invited?: No
26. N.A. Rizvi, S.N. Gettinger, J.W. Goldman, M.D. Hellmann, L.Q. Chow, R. Juergens, H. Borghaei, J.R. Brahmer, Y. Shen, C. Harbison, F. Nathan, N. Ready, S.J. Antonia.Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC).World Congress on Lung Cancer, Vienna, Austria,
Conference Date: 2016/12
Poster
Refereed?: Yes, Invited?: No
27. D. Hao, R. Juergens, S. A. Laurie, M. Mates, M. Tehfe, P. Bradbury, C. Kollmannsberger, P. Ellis, J. Hilton, P. Brown-Walker, L. Seymour.A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226).EORTC-NCI-AACR Symposium, Munich, Germany,
Conference Date: 2016/11
Poster
Refereed?: Yes, Invited?: No
28. M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-Ares, M. Steins, E. Felip, M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, J.N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, W.J. Geese, P. Bhagavatheeswaran, A. Chen, D.P. Carbone.CheckMate 026: A Phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC.European Society of Medical Oncology Annual Meeting, Copenhagen, Denmark,
Conference Date: 2016/10
Poster
Refereed?: Yes, Invited?: No
29. Matthew David Hellmann, Scott N. Gettinger, Jonathan Wade Goldman, Julie R. Brahmer, Hossein Borghaei, Laura Q. Chow, Neal Ready, David E. Gerber, Rosalyn A. Juergens, Frances A. Shepherd, Scott Andrew Laurie, Ye Zhou, William J. Geese, Shruti Agrawal, Xuemei Li, and Scott Joseph Antonia. (2016). CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. ASCO, Chicago, United States of America,
Conference Date: 2016/5
Abstract
Co-Author
Published
30. Naiyer Rizvi, Scott N. Gettinger, Jonathan Goldman, Matthew D. Hellmann, Laura Q. Chow, Rosalyn Juergens, Hossein Borghaei, Julie Brahmer, Yun Shen, Christopher Harbison, Faith Nathan, Neal E. Ready, Scott Antonia. (2015). Safety and efficacy of first?line nivolumab (NIVO; anti?programmed death-1 [PD?1]) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). ECCO, ,
Abstract
Co-Author
Published

31. Rosalyn Juergens, Som Mukherjee, Sebastien Hotte, Hal Hirte, Elaine McWhirter, Anita Bane, Mark Levine, Karen Gulenchyn, John Valliant. (2015). Imaging the Insulin-Like Growth Factor Receptor 1 (IGF-1R): A First in Human Phase I Imaging Clinical Trial. Canadian Cancer Research Conference, Montreal, Canada, Conference Date: 2015/9
Abstract
First Listed Author
Published
32. Scott N. Gettinger, Frances A. Shepherd, Scott Joseph Antonia, Julie R. Brahmer, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthi, Allen C. Chen, Naiyer A. Rizvi. (2015). First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. ASCO, Chicago, United States of America, Conference Date: 2015/5
Abstract
Co-Author
Published
33. S.N. Gettinger, M.D. Hellmann, F.A. Shepherd, S.J. Antonia, J. Brahmer, L.Q. Chow, J. Goldman, R. Juergens, H. Borghaei, N.E. Ready, D.E. Gerber, F. Nathan, Y. Shen, C.T. Harbison, N. Rizvi. (2014). First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC). CMTSO, , Abstract
Co-Author
Published
34. S. Gettinger, N. Rizvi, L. Q. Chow, H. Borghaei, J. R. Brahmer, R. Juergens, F. A. Shepherd, S. A. Laurie, D. E. Gerber, J. W. Goldman, Y. Shen, C. Harbison, A. Chen, S. J. Antonia. (2014). 1054PD - Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) or erlotinib (ERL) in advanced non-small cell lung cancer (NSCLC). ESMO 2014 Congress, , Conference Date: 2014/9
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No
35. Scott N. Gettinger, Frances A. Shepherd, Scott Joseph Antonia, Julie R. Brahmer, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthi, Allen C. Chen, and Naiyer A. Rizvi. (2014). First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. American Society of Clinical Oncology Annual Meeting 2014, , Conference Date: 2014/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No
36. Scott Joseph Antonia, Scott N. Gettinger, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Allen C. Chen, Neal Ready, and Naiyer A. Rizvi. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. American Society of Clinical Oncology Annual Meeting 2014, , Conference Date: 2014/6
Abstract
Co-Author
Published, Invited?: No

37. Scott Joseph Antonia, Julie R. Brahmer, Scott N. Gettinger, Laura Quan Man Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott Andrew Laurie, David E. Gerber, Jonathan Wade Goldman, Yun Shen, Christopher Harbison, Suresh Alaparthi, Allen C. Chen, Hossein Borghaei, and Naiyer A. Rizvi. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting 2014, ,
Conference Date: 2014/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No
38. Naiyer A. Rizvi, Scott J. Antonia, Laura Q. Chow, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei, Frances A. Shepherd, Scott Andrew Laurie, David E. Gerber, Jonathan Wade Goldman, Yun Shen, C. (2013). A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naïve non-small cell lung cancer (NSCLC) patients (pts). ASCO, Chicago, ,
Conference Date: 2013/5
Poster
Co-Author
Accepted
39. Mark Socinski, Rosalyn Juergens, Fiona Blackhall, Rafael Rosell, Iman El-Hariry, Vojo Vukovic, Florentina Teofilovici, Isra Isa, Glenwood Goss. (2012). The CHIARA Trial (NCT01562015): A single arm, phase 2 study of ganetespib in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement (ALK-positive NSCLC). ESMO, Vienna, Austria,
Conference Date: 2012/9
Abstract
Co-Author
Published
40. J.M. Wrangle, H.P. Mohammad, A. Abukhdeir, R.A. Juergens, K. Harbom, K. Rodgers, J. Shin, C.A. Zahnow, S. Baylin, J. Herman, C.M. Rudin, M.V. Brock. (2012). Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations. ASCO, Chicago, IL, ,
Conference Date: 2012/5
Abstract
Co-Author
Published, Invited?: Yes
41. J.M. Wrangle, R.A. Juergens, F. Vendetti, , B. Coleman, R.S. Sebree, M.A. Rudek, S. Belinsky, J. Herman, S. Baylin, C.M. Rudin, M.V. Brock. (2011). Biomarker Development for a Phase II Study of Combination Epigenetic Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). World Conference on Lung Cancer, Amsterdam, Netherlands, ,
Conference Date: 2011/7
Poster
Co-Author
Published, Invited?: Yes
42. B. Halmos, J. Bokar, P. Fu, D. Adelstein, R. Juergens, M.B. Rodal, A. Dowlati. (2011). A Phase I Study of the combination of oxaliplatin / docetaxel and vandetanib for the treatment of advanced gastroesophageal (GE) cancer. ASCO, Chicago, IL, ,
Conference Date: 2011/6
Poster
Co-Author
Published, Invited?: Yes

43. V.M. Macaulay, M.R. Middleton, S.G. Eckhardt, R. Juergens, C. M. Rudin, A. Manukyants, S. Gogov, S. Poondru, R. Gedrich and S. Gadgeel. (2011). Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.ASCO, Chicago, IL, ,
Conference Date: 2011/6
Poster
Co-Author
Published, Invited?: Yes

44. R.A. Juergens, F. Vendetti, J. Wrangle, B. Coleman, R.S. Sebree, M.A. Rudek, S.Belinsky, M. Brock, J. Herman, S. Baylin, C.M. Rudin. (2011). A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer (NSCLC).Amercian Association for Cancer Research Annual Meeting, Orlando, FL, ,
Conference Date: 2011/4
Abstract
First Listed Author
Published, Invited?: Yes

45. R.A. Juergens, F. Vendetti, J. Wrangle, B. Coleman, R.S. Sebree, M.A. Rudek, S.Belinsky, M. Brock, J. Herman, S. Baylin, C.M. Rudin. (2011). Analysis of a Phase II trial of 5-azacitidine(5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer.5th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy., San Diego, CA, ,
Conference Date: 2011/1
Poster
First Listed Author
Published, Invited?: Yes

46. V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, A. W. Stephens, S. Poondru, S. P. McCarthy, and S. M. Gadgeel. (2010). Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.ASCO Meeting Abstracts. ASCO, (3016),
Conference Date: 2010/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: Yes

Date Submitted: 2024-09-30 13:55:18

Confirmation Number: 1835275

Template: Full CV

Dr. Monsur Ali

Correspondence language: English

Sex: Male

Date of Birth: 6/24

Canadian Residency Status: Canadian Citizen

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

1280 Main St W, ETB 303
Hamilton Ontario L8S 4L8
Canada

Telephone

Mobile (*) 1-289-4400938

Email

Work (*) monsali@mcmaster.ca

Website

Social Media <https://scholar.google.com/citations?user=ww8NdAsAAAAJ>

Dr. Monsur Ali

Language Skills

| Language | Read | Write | Speak | Understand | Peer Review |
|----------|------|-------|-------|------------|-------------|
| English | Yes | Yes | Yes | Yes | Yes |

Degrees

| | |
|------------------|---|
| 2000/1 - 2003/3 | Doctorate, PhD in Chemo-Pharmaceutical Sciences, Chemistry and Biochemistry of nucleic acids, Kyushu University Degree Status: Completed Thesis Title: Application of 2-amino-6-vinylpurine for post-synthetic modification of oligonucleotides Supervisors: Shigeki Sasaki, 2000/1 - 2003/3 |
| 1993/3 - 1995/4 | Master's Thesis, Biochemistry and Molecular Biology, Isolation, purification and characterization of amylase from Bacillus Sphaericus, University of Dhaka-Bangladesh Degree Status: Completed Thesis Title: Studies on extracellular amylase from Bacillus Sphaericus Supervisors: Prof. Dr. Anwar Hossain, 1993/3 - 1995/5 |
| 1989/1 - 1994/12 | Bachelor's Honours, BSc (Hons) in Biochemistry, Molecular Biology, University of Dhaka-Bangladesh Degree Status: Completed |

User Profile

Researcher Status: Researcher
 Research Career Start Date: 2006/01/01
 Engaged in Clinical Research?: No

Key Theory / Methodology: In vitro selection to generate DNazymes and aptamers

Research Interests: My research interest is multidisciplinary specially in the development of point-of-care (POC) diagnostics for infectious and human diseases. I am also interested in developing innovative therapeutics with the use of DNA aptamers and DNazymes.

Research Experience Summary: I have been actively involved in research for more than 20 years. I have gained substantial experience and expertise in the functional nucleic acids (DNA aptamers, DNazyme, antisense, miRNA). I have generated DNA aptamers and DNazymes for variety of targets, and developed paper-based and solution based assay systems for diagnostic applications. I am the pioneer of generating DNazymes that specifically sense bacteria and developed different formats of paper-based assay systems.

Research Specialization Keywords: aptamer, DNazymes, in vitro selection

Research Centres: McMaster University

Disciplines Trained In: Biochemistry

Research Disciplines: Biochemistry

Areas of Research: Diagnostic Techniques

Employment

2023/1 Sessional Faculty
 Biotechnology, W Booth School of Engineering Practice and Technology, McMaster University
 Part-time, Sessional
 Tenure Status: Non Tenure Track
 As a sessional faculty, I provide lectures and serve as instructor to conduct laboratory works for undergraduate students for the W Booth Engineering Practice and Technology program at McMaster University

Affiliations

The primary affiliation is denoted by (*)

(*) 2014/7 Research Associate and Sessional Faculty, McMaster University
 Teaching and Research

Research Funding History

Completed [n=1]

2015/5 - 2020/4 National Institute of Allergy and Infectious Diseases (NIAID) R01 Award, Canada lung cancer ambition grant, Grant, Operating
 Co-applicant Clinical Research Project?: Yes
 Project Description: This funding was awarded to develop DNAzyme-based diagnostics for infectious diseases. I was a Co-PI of this funding and brought my portion at McMaster University in Canada as sub award. Here at McMaster, I generated a DNAzyme for *Klebsiella pneumoniae* and developed a simple paper microwell type assay for KP.

Funding Sources:

Canadian Lung Association (CLA)
 Lung Cancer ambition grant
 Total Funding - 50,000
 Portion of Funding Received - 50,000
 Funding Competitive?: No

Courses Taught

Instructor, W Booth School of Engineering practice and Technology, McMaster University
 Course Title: 1) Genomic and Proteomics 2) Biochemistry
 Course Code: 4GP3, 2BC3
 Course Level: Undergraduate
 Section: 4GP3-L01, 4GP3-L02, 2BC3-L03, 2BC3-L04
 Academic Session: Winter
 Number of Students: 40

Journal Review Activities

Reviewing research articles,Langmuir,American Chemical Society

Number of Works Reviewed / Refereed: 1

Reviewing research articles,Letters in Applied Microbiology,Oxford Academic

Number of Works Reviewed / Refereed: 1

Reviewing research articles,New Journal of Chemistry,Royal Society of Chemistry

Number of Works Reviewed / Refereed: 1

Reviewing research articles,Talanta,ScienceDirect

Number of Works Reviewed / Refereed: 3

Reviewing research articles,Nucleic Acids Research,Oxford University press

Number of Works Reviewed / Refereed: 5

Reviewing research articles,Plos One,Plos

Number of Works Reviewed / Refereed: 2

Reviewing research articles,Environmental Science: Water Research & Technology,Royal Society of Chemistry

Number of Works Reviewed / Refereed: 2

Reviewing research articles,Food Science & Nutrition,Wiley

Number of Works Reviewed / Refereed: 2

Reviewing research articles,Sensors,MDPI

Number of Works Reviewed / Refereed: 4

Reviewing research articles,Analytical Biochemistry,ScienceDirect

Number of Works Reviewed / Refereed: 2

Reviewing research articles,Analytical Chemistry,American Chemical Society

Number of Works Reviewed / Refereed: 3

Reviewing research articles,Biosensors,MDPI

Number of Works Reviewed / Refereed: 6

Reviewing research articles,Lab on a chip,Royal Society of Chemistry

Number of Works Reviewed / Refereed: 1

Reviewing research articles,Influenza and Other Respiratory Viruses,Wiley

Number of Works Reviewed / Refereed: 1

Reviewing research articles,Trends in Analytical Chemistry,ScienceDirect

Number of Works Reviewed / Refereed: 3

Knowledge and Technology Translation

2022/3 - 2023/3

Product development, Technology, Product, Process, Service Improvement/Development Group/Organization/Business Serviced: CytoDiagnostics Inc

Target Stakeholder: Industrial Association/Producer Group

Outcome / Deliverable: Developed a rapid test for marine algae and toxin for water test

International Collaboration Activities

2012/1 - 2018/6

Co-PI, United States of America

Developed a DNAzyme for Klebsiella pneumoniae and developed an easy to use paper based spot test

Most Significant Contributions

- 2011/3 Fluorogenic DNAzyme probes as bacterial indicator
This work was the pioneer in the field of DNAzyme with the ability to sense the presence of specific bacteria. This laid the foundation of generating DNAzyme probes for many other bacteria and cancer.

Presentations

1. (2019). A Printable Paper-Based Hydrogel Microarray for Drug Screening Enabling Discrimination between True and Promiscuous Enzyme Inhibitors. AIChE Annual Meeting, Canada
Invited?: No, Keynote?: No, Competitive?: Yes

Publications

Journal Articles

1. M Monsur Ali, Manali Mukherjee, Katherine Radford, Zil Patel, Alfredo Capretta, Parameswaran Nair, John D Brennan. (2023). A Rapid Sputum-based Lateral Flow Assay for Airway Eosinophilia using an RNA-cleaving DNAzyme Selected for Eosinophil Peroxidase. *Angewandte Chemie International Edition English*. 62(38): e202307451.
First Listed Author
Published, Wiley, Germany
Refereed?: Yes, Open Access?: No, Synthesis?: No
2. M. Monsur Ali, Michael G. Wolfe, Manali Mukherjee, Katherine Radford, Zil Patel, Dawn White, Julijana Milojevic, Alfredo Capretta, Parameswaran Nair & John D. Brennan. (2022). A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer. *Scientific Reports*. 12(1): 22476.
First Listed Author
Published, Nature publishing group,
Refereed?: Yes, Open Access?: Yes
3. M Monsur Ali, Ryan Silva, Dawn White, Saeed Mohammadi, Yingfu Li , Alfredo Capretta, John D Brennan. (2022). A Lateral Flow Test for *Staphylococcus aureus* in Nasal Mucus Using a New DNAzyme as the Recognition Element. *Angew Chem Int Ed Engl* .61(3): e202112346.
First Listed Author
Published, Wiley,
Refereed?: Yes, Open Access?: No
4. Michael G. WolfeM. Monsur AliJohn D. Brennan. (2019). Enzymatic litmus test for selective colorimetric detection of C–C single nucleotide polymorphisms. *Analytical Chemistry*. 91: 4735-4740.
Co-Author
Published, American Chemical Society, United States of America
Refereed?: Yes, Open Access?: No
5. Dr. M. Monsur Ali, Michael Wolfe, Kha Tram, Jimmy Gu, Prof. Dr. Carlos D. M. Filipe, Prof. Dr. Yingfu Li, Prof. Dr. John D. Brennan. (2019). A DNAzyme-Based Colorimetric Paper Sensor for *Helicobacter pylori*. *Angew Chem Int Ed Engl*. 58: 9907-9911.
First Listed Author
Published, Wiley, Germany
Refereed?: Yes, Open Access?: No

6. Dr. M. Monsur Ali, Dr. Anatoly Slepkin, Dr. Ellena Peterson, Dr. Weian Zhao. (2019). A simple DNAzyme-based fluorescent assay for *Klebsiella pneumoniae*. *ChemBioChem*. 20: 906-910.
First Listed Author
Published, Wiley, Germany
Refereed?: Yes, Open Access?: No
7. Hanie Yousefi, M. Monsur Ali, Hsuan-Ming Su, Carlos D.M. Filipe, and Tohid F. Didar. (2018). Sentinel wraps: real-time monitoring of food contamination by printing DNAzyme probes on food packaging. *ACS Nano*. 12: 3287-3294.
Published, American Chemical Society, United States of America
Refereed?: Yes, Open Access?: No
8. Hany Anany, Lubov Brovko, Noha K. El Dougdoug, Jennifer Sohar, Heather Fenn, Nada Alasiri, Tarik Jabrane, Patrice Mangin, M. Monsur Ali, Balamurali Kannan, Carlos D. M. Filipe & Mansel W. Griffiths. (2018). Print to detect: a rapid and ultrasensitive phage-based dipstick assay for foodborne pathogens. *Anal Bioanal Chem*. 410: 1217-12.
Co-Author
Published, Springerlink,
Refereed?: Yes, Open Access?: No

Book Chapters

1. D.-K. Kang, J. Lu, W. Zhang, E. Chang, M.A. Eckert, M.M. Ali, W. Zhao, XiuJun (James) Li. (2021). Microfluidics for analyzing stem cells, *Microfluidic Devices for Biomedical Applications*. Microfluidic Devices for Biomedical Applications. Second Edition: 437-487.
Co-Author
Published, Woodhead,
Refereed?: Yes

Intellectual Property

Patents

1. Printable hydrogels for biomolecule immobilization and stabilization. United States of America. US20200256860A1.
Patent Status: Pending
Inventors: Rabia MateenMonsur AliTodd Hoare
2. DNA aptamers for eosinophil peroxidase detection. United States of America. US Patent App. 17/966,575. 2022/10/14.
Patent Status: Pending
Inventors: John D. BrennanMonsur AliMichael WolfeDawn WhiteManali MukherjeeParameswaran NairAlfredo Capretta
3. DNAzyme-based sensor for *Helicobacter pylori*. United States of America. US Patent 11,549,945. 2020/05/15.
Patent Status: Granted/Issued
Year Issued: 2023
Inventors: M Ali, D White, S Mohammadi, JD Brennan, Y Li, A Capretta
4. Method of long-term preservation of chemical and biological species using sugar glasses. United States of America. US Patent 11,040,015. 2018/10/16.
Patent Status: Granted/Issued
Year Issued: 2021
Inventors: VHY Leung, S Jahanshahi-Anbuhi, C Filipe, MM Ali